Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically ~~and posted on its corporate Website, if any,~~ every Interactive Data File required to be submitted ~~and posted~~ pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit ~~and post~~ such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

As of ~~May 15,~~November 9, 2018, ~~26,634,475~~34,546,518 shares of the registrant’s common stock were outstanding.

XpresSpa Group, Inc. and Subsidiaries

Table of Contents

Part I- FINANCIAL INFORMATION

Item 1.

Condensed Consolidated Financial Statements

XpresSpa Group, Inc. and Subsidiaries

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share data)

March 31,
2018
(Unaudited)
December 31,
2017
Current assets
Cash and cash equivalents $ 3,554 $ 6,368
Inventory 1,050 1,159
Other current assets 1,000 2,120
Assets held for disposal 717 6,446
Total current assets 6,321 16,093

Restricted cash 487 487
Property and equipment, net 15,928 15,797
Intangible assets, net 11,007 11,547
Goodwill — 19,630
Other assets 3,765 1,686
Total assets $ 37,508 $ 65,240

Current liabilities
Accounts payable, accrued expenses and other current liabilities $ 8,560 $ 8,736
Liabilities held for disposal — 3,761
Total current liabilities 8,560 12,497

Debt 6,500 6,500
Other liabilities 433 404
Total liabilities 15,493 19,401
Commitments and contingencies (see Note 12)

Stockholders’ equity
Series A Convertible Preferred stock, $0.01 par value per share; 500,000 shares authorized; 6,968 issued and none outstanding — —
Series B Convertible Preferred stock, $0.01 par value per share; 5,000,000 shares authorized; 1,666,667 issued and none outstanding — —
Series C Junior Preferred stock, $0.01 par value per share; 300,000 shares authorized; none issued and outstanding — —
Series D Convertible Preferred Stock, $0.01 par value per share; 500,000 shares authorized; 475,208 shares issued and 420,541 shares outstanding with a liquidation value of $20,186 as of March 31, 2018 and December 31, 2017 4 4
Common stock, $0.01 par value per share; 150,000,000 shares authorized; 26,634,475 and 26,545,690 issued and outstanding as of March 31, 2018 and December 31, 2017, respectively 266 265
Additional paid-in capital 290,707 290,396
Accumulated deficit (273,641 ) (249,708 )
Accumulated other comprehensive loss (140 ) (74 )
Total stockholders’ equity attributable to the Company
17,196
40,883
Noncontrolling interests 4,819 4,956
Total stockholders’ equity
22,015
45,839
Total liabilities and stockholders’ equity $ 37,508 $ 65,240

	September 30, 2018 (Unaudited)			December 31, 2017
Current assets
Cash and cash equivalents	$	2,525		$	6,368
Inventory		802			1,159
Other current assets		591			2,120
Assets held for disposal		109			6,446
Total current assets		4,027			16,093

Restricted cash		487			487
Property and equipment, net		15,005			15,797
Intangible assets, net		9,789			11,547
Goodwill		—			19,630
Other assets		3,356			1,686
Total assets	$	32,664		$	65,240

Current liabilities
Accounts payable, accrued expenses and other current liabilities	$	7,641		$	8,736
Convertible notes, net		1,610			—
Liabilities held for disposal		40			3,761
Total current liabilities		9,291			12,497

Debt		6,500			6,500
Convertible notes, net		398			—
Derivative warrant liabilities		455			34
Other liabilities		265			370
Total liabilities		16,909			19,401
Commitments and contingencies (see Note 13)

Stockholders’ equity
Series A Convertible Preferred stock, $0.01 par value per share; 6,968 shares authorized; 6,968 issued and none outstanding		—			—
Series B Convertible Preferred stock, $0.01 par value per share; 1,609,167 shares authorized; 1,609,167 issued and none outstanding		—			—
Series C Junior Preferred stock, $0.01 par value per share; 300,000 shares authorized; none issued and outstanding		—			—
Series D Convertible Preferred Stock, $0.01 par value per share; 500,000 shares authorized; 475,208 shares issued and 420,541 shares outstanding with a liquidation value of $20,186		4			4
Common stock, $0.01 par value per share; 150,000,000 shares authorized; 31,919,511 and 26,545,690 issued and outstanding as of September 30, 2018 and December 31, 2017, respectively		319			265
Additional paid-in capital		291,989			290,396
Accumulated deficit		(280,351	)		(249,708	)
Accumulated other comprehensive loss		(279	)		(74	)
Total stockholders’ equity attributable to the Company		11,682			40,883
Noncontrolling interests		4,073			4,956
Total stockholders’ equity		15,755			45,839
Total liabilities and stockholders’ equity	$	32,664		$	65,240

The accompanying notes form an integral part of these condensed consolidated financial statements.

XpresSpa Group, Inc. and Subsidiaries

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited)

(In thousands, except share and per share data)

	Three months ended March 31,						Three months ended September 30,						Nine months ended September 30,
	2018			2017			2018			2017			2018			2017
Revenue
Products and services	$	11,800		$	10,984		$	12,922		$	12,652		$	37,760		$	36,563
Other		800			100			—			200			800			300
Total revenue		12,600			11,084			12,922			12,852			38,560			36,863

Cost of sales
Labor		6,210			5,309			5,997			7,086			18,697			18,178
Occupancy		2,060			1,771			1,996			1,950			6,216			5,704
Products and other operating costs		1,507			1,854			1,992			1,437			5,208			6,044
Total cost of sales		9,777			8,934			9,985			10,473			30,121			29,926
Depreciation and amortization		1,653			1,726			1,879			1,722			5,375			6,379
Goodwill impairment		19,630			—			—			—			19,630			—
General and administrative*		4,596			4,993			3,943			4,180			12,443			13,037
Total operating expenses		35,656			15,653			15,807			16,375			67,569			49,342
Operating loss from continuing operations		(23,056	)		(4,569	)		(2,885	)		(3,523	)		(29,009	)		(12,479	)
Interest expense		(183	)		(189	)		(624	)		(183	)		(1,212	)		(549	)
Other non-operating income (expense), net		(90	)		114			378			(82	)		877			(17	)
Loss from continuing operations before income taxes		(23,329	)		(4,644	)		(3,131	)		(3,788	)		(29,344	)		(13,045	)
Income tax benefit (expense)		84			(227	)		66			(57	)		198			(284	)
Consolidated net loss from continuing operations		(23,245	)		(4,871	)		(3,065	)		(3,845	)		(29,146	)		(13,329	)
Loss from discontinued operations before income taxes*		(605	)		(1,478	)		—			(699	)		(1,115	)		(4,474	)
Income tax benefit (expense)		—			—			—			—			—			—
Consolidated net loss from discontinued operations		(605	)		(1,478	)		—			(699	)		(1,115	)		(4,474	)
Consolidated net loss		(23,850	)		(6,349	)		(3,065	)		(4,544	)		(30,261	)		(17,803	)
Net income attributable to noncontrolling interests		(83	)		(76	)		(122	)		(153	)		(382	)		(329	)
Net loss attributable to the Company	$	(23,933	)	$	(6,425	)	$	(3,187	)	$	(4,697	)	$	(30,643	)	$	(18,132	)

Consolidated net loss from continuing operations	$	(23,245	)	$	(4,871	)	$	(3,065	)	$	(3,845	)	$	(29,146	)	$	(13,329	)
Other comprehensive loss from continuing operations		(66	)		(44	)
Other comprehensive income (loss) from continuing operations								(3	)		31			(205	)		(120	)
Comprehensive loss from continuing operations		(23,311	)		(4,915	)		(3,068	)		(3,814	)		(29,351	)		(13,449	)
Consolidated net loss from discontinued operations		(605	)		(1,478	)		—			(699	)		(1,115	)		(4,474	)
Other comprehensive loss from discontinued operations		—			—			—			—			—			—
Comprehensive loss from continuing operations		(605	)		(1,478	)
Comprehensive loss from discontinued operations								—			(699	)		(1,115	)		(4,474	)
Comprehensive loss	$	(23,916	)	$	(6,393	)	$	(3,068	)	$	(4,513	)	$	(30,466	)	$	(17,923	)

Loss per share
Loss per share from continuing operations	$	(0.88	)	$	(0.26	)	$	(0.11	)	$	(0.16	)	$	(1.08	)	$	(0.65	)
Loss per share from discontinued operations		(0.02	)		(0.08	)		—			(0.04	)		(0.04	)		(0.22	)
Total basic and diluted net loss per share	$	(0.90	)	$	(0.34	)	$	(0.11	)	$	(0.20	)	$	(1.12	)	$	(0.87	)
Weighted-average number of shares outstanding during the period
Weighted-average number of shares outstanding during the period:
Basic		26,592,781			18,862,715			28,352,284			24,144,002			27,268,792			20,852,034
Diluted		26,592,781			18,862,715			28,352,284			24,144,002			27,268,792			20,852,034

*Includes stock-based compensation expense, as follows:
General and administrative	$	312		$	547		$	194		$	662		$	765		$	1,752
Discontinued operations		—			194			—			44			—			427
Total stock-based compensation expense	$	312		$	741		$	194		$	706		$	765		$	2,179

The accompanying notes form an integral part of these condensed consolidated financial statements.

XpresSpa Group, Inc. and Subsidiaries

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY

(Unaudited)

(In thousands)

	Preferred stock		Common stock		Additional paid- in capital			Accumulated deficit			Accumulated other comprehensive loss			Total Company equity			Non- controlling interest			Total equity			Preferred stock		Common stock		Additional paid- in capital			Accumulated deficit			Accumulated other comprehensive loss			Total Company equity			Non- controlling interest			Total equity
December 31, 2017	$	4	$	265	$	290,396		$	(249,708	)	$	(74	)	$	40,883		$	4,956		$	45,839		$	4	$	265	$	290,396		$	(249,708	)	$	(74	)	$	40,883		$	4,956		$	45,839
Vesting of restricted stock units (“RSUs”)		—		1		(1	)		—			—			—			—			—			—		6		(6	)		—			—			—			—			—
Issuance of equity warrants																								—		—		64			—			—			64			—			64
Issuance of common stock for repayment of debt and interest																								—		48		770			—			—			818			—			818
Stock-based compensation		—		—		312			—			—			312			—			312			—		—		765			—			—			765			—			765
Net loss for the period		—		—		—			(23,933	)		—			(23,933	)		83			(23,850	)		—		—		—			(30,643	)		—			(30,643	)		382			(30,261	)
Foreign currency translation		—		—		—			—			(66	)		(66	)		—			(66	)		—		—		—			—			(205	)		(205	)		—			(205	)
Contributions from noncontrolling interests																								—		—		—			—			—			—			119			119
Distributions to noncontrolling interests		—		—		—			—			—			—			(220	)		(220	)		—		—		—			—			—			—			(1,384	)		(1,384	)
March 31, 2018	$	4	$	266	$	290,707		$	(273,641	)	$	(140	)	$	17,196		$	4,819		$	22,015
September 30, 2018																							$	4	$	319	$	291,989		$	(280,351	)	$	(279	)	$	11,682		$	4,073		$	15,755

	Preferred stock		Common stock		Additional paid- in capital		Accumulated deficit			Accumulated other comprehensive loss			Total Company equity			Non- controlling interest		Total equity			Preferred stock			Common stock		Additional paid- in capital			Accumulated deficit			Accumulated other comprehensive loss			Total Company equity			Non- controlling interest			Total equity
December 31, 2016	$	5	$	183	$	280,221	$	(220,868	)	$	(13	)	$	59,528		$	4,641	$	64,169		$	5		$	183	$	280,221		$	(220,868	)	$	(13	)	$	59,528		$	4,641		$	64,169
Issuance of common stock for services		—		—		11		—			—			11			—		11			—			—		20			—			—			20			—			20
Shares of common stock issued for the acquisition of Excalibur		—		9		1,800		—			—			1,809			—		1,809
Issuance of common stock for acquisition of Excalibur																						—			9		1,800			—			—			1,809			—			1,809
Net proceeds from sale and issuance of shares of common stock in public offering																						—			69		6,515			—			—			6,584			—			6,584
Decrease in shares of preferred stock issued to XpresSpa sellers																						—			—		(908	)		—			—			(908	)		—			(908	)
Conversion of preferred stock to common stock																						(1	)		4		(4	)		—			—			(1	)		—			(1	)
Stock-based compensation		—		—		741		—			—			741			—		741			—			—		2,179			—			—			2,179			—			2,179
Net loss for the period		—		—		—		(6,425	)		—			(6,425	)		76		(6,349	)		—			—		—			(18,132	)		—			(18,132	)		329			(17,803	)
Foreign currency translation		—		—		—		—			(44	)		(44	)		—		(44	)		—			—		—			—			(120	)		(120	)		—			(120	)
March 31, 2017	$	5	$	192	$	282,773	$	(227,293	)	$	(57	)	$	55,620		$	4,717	$	60,337
Contributions from noncontrolling interests																						—			—		—			—			—			—			272			272
Distributions to noncontrolling interests																						—			—		—			—			—			—			(365	)		(365	)
September 30, 2017																					$	4		$	265	$	289,823		$	(239,000	)	$	(133	)	$	50,959		$	4,877		$	55,836

The accompanying notes form an integral part of these condensed consolidated financial statements.

XpresSpa Group, Inc. and Subsidiaries

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(In thousands)

	Three months ended March 31,						Nine months ended September 30,
	2018			2017			2018			2017
Cash flows from operating activities
Consolidated net loss	$	(23,850	)	$	(6,349	)	$	(30,261	)	$	(17,803	)
Consolidated net loss from discontinued operations		(605	)		(1,478	)		(1,115	)		(4,474	)
Consolidated net loss from continuing operations		(23,245	)		(4,871	)		(29,146	)		(13,329	)
Adjustments to reconcile consolidated net loss from continuing operations to net cash used in operating activities:
Items not affecting cash flows
Depreciation and amortization		1,653			1,726			5,375			6,379
Goodwill impairment		19,630			—			19,630			—
Stock-based compensation		312			741			765			1,752
Issuance of shares of common stock		—			1,820			—			1,829
Change in fair value of derivative warrant liabilities		(33	)		(26	)
Issuance of shares of common stock for repayment of debt and interest								169			—
Issuance of equity warrants								64			—
Gain on disposal of asset								—			(148	)
Amortization of debt discount and debt issuance costs								589			—
Change in fair value of derivative warrant liabilities – May 2015								(33	)		(207	)
Change in fair value of derivative warrant liabilities – May 2018								(1,508	)		—
Conversion of shares of preferred stock to shares of common stock								—			(1	)
Contingent liability assumed from acquisition		—			316			—			(316	)
Gain on the sale of patents		(450	)		—			(450	)		—
Changes in current assets and liabilities net of effects of acquisition
Changes in assets and liabilities
Decrease in inventory		109			219			357			967
Decrease (increase) in other current assets and other assets		(1,559	)		421			(741	)		1,229
Decrease in accounts payable, accrued expenses and other current liabilities		(176	)		(2,336	)		(1,095	)		(4,189	)
Increase in other liabilities		62			169			(105	)		791
Net cash used in operating activities – continuing operations		(3,697	)		(1,821	)		(6,129	)		(5,243	)
Net cash provided by (used in) operating activities – discontinued operations		1,363			(3,078	)		1,501			(5,716	)
Net cash used in operating activities		(2,334	)		(4,899	)		(4,628	)		(10,959	)
Cash flows from investing activities
Acquisition of property and equipment		(1,178	)		(808	)		(2,682	)		(1,970	)
Acquisition of software		(66	)		—			(143	)		(331	)
Proceeds from the sale of patents		250			—			250			150
Cash received from note receivable		800			—			800			—
Net cash used in investing activities – continuing operations		(194	)		(808	)		(1,775	)		(2,151	)
Net cash used in investing activities – discontinued operations		—			(125	)		—			(738	)
Net cash used in investing activities		(194	)		(933	)		(1,775	)		(2,889	)
Cash flows from financing activities
Cash flows provided by (used in) financing activities
Proceeds from convertible notes and warrants								4,350			—
Debt issuance costs								(320	)		—
Net proceeds from sale and issuance of shares of common stock in public offering								—			6,584
Contributions from noncontrolling interests								119			272
Distributions to noncontrolling interests		(220	)		—			(1,384	)		(365	)
Net cash used in financing activities – continuing operations		(220	)		—
Net cash provided by (used in) financing activities – continuing operations								2,765			6,491
Net cash used in financing activities – discontinued operations		—			(361	)		—			(361	)
Net cash used in financing activities		(220	)		(361	)
Net cash provided by (used in) financing activities								2,765			6,130
Effect of exchange rate changes and foreign currency translation		(66	)		(44	)		(205	)		(120	)
Decrease in cash and cash equivalents		(2,814	)		(6,237	)		(3,843	)		(7,838	)
Cash and cash equivalents at beginning of period		6,368			17,910			6,368			17,910
Cash and cash equivalents at end of period	$	3,554		$	11,673		$	2,525		$	10,072
Cash paid during the period for
Interest	$	150		$	150		$	580		$	580
Non-cash investing and financing transactions
Non-cash acquisition of cost method investment							$	2,075		$	—
Debt discount related to issuance of convertible notes							$	1,962		$	—
Issuance of common stock to repay $649 of debt and interest							$	818		$	—

The accompanying notes form an integral part of these condensed consolidated financial statements.

XpresSpa Group, Inc. and Subsidiaries

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

(In thousands, except for share and per share data)

Note 1. General

On January 5, 2018, FORM Holdings Corp. changed its name to XpresSpa Group, Inc. (“XpresSpa Group” or the “Company”). The Company’s common stock, par value $0.01 per share, which had previously been listed under the trading symbol “FH” on the Nasdaq Capital Market (“Nasdaq”), has been listed under the trading symbol “XSPA” since January 8, 2018. Rebranding to XpresSpa Group aligned the Company’s corporate strategy to build a pure-play health and wellness services company, which the Company commenced following its acquisition of XpresSpa Holdings, LLC (“XpresSpa”) on December 23, 2016.

As a result of the transition to a pure-play health and wellness services company, the Company currently has one operating segment that is also its sole reporting unit, ~~which is comprised of~~ XpresSpa, a leading airport retailer of spa services. XpresSpa is a well-recognized airport spa brand with 57 locations, consisting of 52 domestic and 5 international locations as of ~~March 31,~~September 30, 2018. XpresSpa offers travelers premium spa services, including massage, nail and skin care, as well as spa and travel products.

In October 2017, the Company completed the sale of FLI Charge, Inc. (“FLI Charge”) and, in March 2018, the Company completed the sale of Group Mobile Int’l LLC (“Group Mobile”). These two entities formerly comprised the Company’s technology operating segment, which was ~~eliminated~~discontinued following the disposition of Group Mobile. The results of operations for FLI Charge and Group Mobile are presented in the condensed consolidated statements of operations and comprehensive loss as consolidated net loss from discontinued operations. The carrying amounts of assets and liabilities belonging to Group Mobile are presented in the condensed consolidated balance sheets as assets held for disposal and liabilities held for disposal, respectively, as of ~~March 31,~~September 30, 2018 and December 31, 2017.

The Company owns certain patent portfolios, which it looks to monetize through sales and licensing agreements. During the ~~three-month~~nine-month period ended ~~March 31,~~September 30, 2018, the Company determined that its former intellectual property operating segment would no longer be an area of focus and, as such, will no longer operate as a separate operating segment, as it is not expected to generate any material ~~revenues.~~revenues or operating costs.

~~As of March 31, 2018, the Company had cash and cash equivalents of $3,554. In addition, the Company’s current assets were $6,321 and current liabilities were $8,560 as of March 31, 2018.~~

On May 15, 2018, the Company entered into a securities purchase agreement (the ~~“Agreement”~~“Securities Purchase Agreement”) with certain institutional investors (the “Investors”), pursuant to which the Company agreed to sell up to (i) an aggregate principal amount of $4,438 in 5% Secured Convertible Notes due November 16, 2019, which ~~includes~~included $88 ~~to be~~ issued to Palladium Capital Advisors as Placement Agent (the “Convertible Notes”), convertible into shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”) at a conversion price of $0.62 per share, (ii) Class A Warrants (the “Class A Warrants”) to purchase 7,157,259 shares of Common Stock at an exercise price of $0.62 per share and (iii) Class B Warrants (the “Class B Warrants,” and together with the Class A Warrants, the “Warrants”) to purchase 3,578,630 shares of Common Stock at an exercise price of $0.62 per share. The Convertible Notes bear interest at a rate of 5% per annum. The Convertible Notes are senior secured obligations of the Company and are secured by certain of its personal property. Unless earlier converted or redeemed, the Convertible Notes will mature inon November 16, 2019. The transaction closed on May 17, 2018, at which time the Company ~~expects~~received $4,350 in gross proceeds from the Investors.

On August 14, 2018, the Company and each of the Investors entered into an Amendment Agreement (“Amendment Agreement”) whereby the initial monthly principal repayment and accrued interest due on the Convertible Notes of $351 was settled in 2,067 shares of Common Stock on August 15, 2018. All other material terms of the Securities Purchase Agreement remained unchanged. During the three-month period ended September 30, 2018, several of the Investors converted their monthly principal payments and accrued interest due on the Convertible Notes into shares of Common Stock pursuant to ~~close~~ the ~~transaction~~Amendment Agreement, resulting in the issuance of an additional 2,737 shares of Common Stock.

As of September 30, 2018, the Company’s current assets were $4,027, which included cash and cash equivalents of $2,525. The Company’s current liabilities were $9,291 as ~~soon~~of September 30, 2018, which included $1,610 of convertible notes classified as ~~possible following~~short-term for which principal repayments may be made in Common Stock at the ~~filing~~Company’s election. In addition, included in total current liabilities is approximately $1,661 which relates to obligations that will not settle in cash, and an additional $465 of ~~these financial statements.~~liabilities that are not expected to settle in the next twelve months.

On November 12, 2018, the Company entered into a Product Sale and Marketing Agreement (the “Collaboration Agreement”) with Calm.com, Inc. (“Calm”) primarily related to the display, marketing, promotion, offer for sale and sale of Calm’s products in each of the Company’s branded stores throughout the United States. The Collaboration Agreement resulted in an initial investment by Calm of $2,000 in Series E Preferred Stock, convertible into shares of Common Stock at $0.62 per share, which was received upon the closing of the transaction.

The Company’s management believes that its current cash balance, cash provided from the ~~issuance of the Convertible Notes and Warrants, and~~Calm Collaboration Agreement, cash to be provided by future operating activities, and cash proceeds from the anticipated liquidation of certain investments, will be sufficient to fund its planned operations and ~~scheduled Convertible Notes principal repayments~~pay its liabilities as they become due for at least the next twelve months following the filing date ~~of the filing~~ of these financial statements. At the Company’s election, principal repayments of the Convertible Notes may be made in cash or, subject to certain conditions, in registered shares of Common Stock. In addition, the Company has access to additional sources of financing and may attempt to renegotiate terms of various contracts.

Note 2. Accounting and Reporting Policies

(a) Basis of presentation and principles of consolidation

The accompanying interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“~~U.S.~~ GAAP”) for interim financial information and the instructions to Rule 10-01 of Regulation S-X, and should be read in conjunction with the Company's Annual Report on Form 10-K for the year ended December 31, 2017. The condensed consolidated financial statements include the accounts of the Company, all entities that are wholly-owned by the Company, and all entities in which the Company has a controlling financial interest. All adjustments that, in the opinion of management, are necessary for a fair presentation for the periods presented have been reflected by the Company. Such adjustments are of a normal, recurring nature. The results of operations for the ~~three-month period~~three- and nine-month periods ended ~~March 31,~~September 30, 2018 are not necessarily indicative of the results that may be expected for the entire fiscal year or for any other interim period. All significant intercompany balances and transactions have been eliminated in consolidation.

(b) Use of estimates

The preparation of the accompanying condensed consolidated financial statements in conformity with ~~U.S.~~ GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses for the periods presented. Actual results may differ from such estimates. Significant items subject to such estimates and assumptions include the Company’s intangible assets, investments classified as other assets, the useful lives of the Company’s intangible assets, the valuation of the Company’s derivative warrant liabilities, the valuation of stock-based compensation, deferred tax assets and liabilities, income tax uncertainties, and other contingencies.

(c) Cash and ~~Cash Equivalents~~cash equivalents

The Company maintains cash in checking accounts with financial institutions. The Company has established guidelines relating to diversification and maturities of its investments in order to minimize credit risk and maintain high liquidity of funds. Cash equivalents include amounts due from third-party financial institutions for credit and debit card transactions. These items typically settle in less than five days. As of ~~March 31,~~September 30, 2018, the Company held significant portions of its cash balance in overseas accounts, totaling ~~$2,661,~~$1,081, which is not insured by the Federal Deposit Insurance Corporation (“FDIC”). If the Company were to distribute the amounts held overseas, the Company would need to follow an approval process as defined in its operating and partnership agreements, which may delay the availability of cash to the Company.

(d) Revenue recognition

The Company recognizes revenue from the sale of XpresSpa products and services at the point of sale, net of discounts and applicable sales taxes. Revenues from the XpresSpa wholesale and e-commerce businesses are recorded at the time goods are shipped. The Company excludes all sales taxes assessed to its customers. Sales taxes assessed on revenues are included in accounts payable, accrued expenses and other current liabilities in the condensed consolidated balance sheets until remitted to the state agencies.

Other revenue relates to one-time intellectual property licenses as well as the sale of certain of the Company’s intellectual property. Revenue from patent licensing is recognized when the Company transfers promised intellectual property rights to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those intellectual property rights. Currently, revenue arrangements related to intellectual property provide for the payment of contractually determined fees and other consideration for the grant of certain intellectual property rights related to the Company’s patents. These rights typically include some combination of the following: (i) the grant of a non-exclusive, retroactive and future license to manufacture and/or sell products covered by patents, (ii) the release of the licensee from certain claims, and (iii) the dismissal of any pending litigation. The intellectual property rights granted typically extend until the expiration of the related patents. Pursuant to the terms of these agreements, the Company has no further obligation with respect to the grant of the non-exclusive retroactive and future licenses, covenants-not-to-sue, releases, and other deliverables, including no express or implied obligation on the Company’s part to maintain or upgrade the related technology, or provide future support or services. Generally, the agreements provide for the grant of the licenses, covenants-not-to-sue, releases, and other significant deliverables upon execution of the agreement, or upon receipt of the upfront payment. As such, the earnings process is complete and revenue is recognized upon the execution of the agreement, receipt of the upfront fee, and transfer of the promised intellectual property rights.

(e) Cost of sales

Cost of sales consists of store-level costs. Store-level costs include all costs that are directly attributable to the store operations and include:

payroll and related benefits for store operations and store-level management;

rent, percentage rent and occupancy costs;

the cost of merchandise;

freight, shipping and handling costs;

production costs;

inventory shortage and valuation adjustments, including purchase price allocation increase in fair values which was recorded as part of acquisition; and

costs associated with sourcing operations.

Cost of sales related to the Company’s intellectual property mainly includes expenses incurred in connection with the Company’s patent licensing and enforcement activities, patent-related legal expenses paid to external patent counsel (including contingent legal fees), licensing and enforcement related research, consulting and other expenses paid to third parties, as well as related internal payroll expenses.

(f) Investments

The Company accounts for its investments in other entities using the cost method of accounting when the Company has no substantial influence over, and the investment is less than 20% of, the investee entity. Under the cost method, the investment is recorded at cost, which approximates fair value, on the date of acquisition. The Company performs an assessment for impairment on at least an annual basis, or when there is an indication that cost exceeds fair value.

(g) Fair value measurements

The Company measures fair value in accordance with ~~FASB ASC~~Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820-10,Fair Value Measurements and Disclosures. FASB ASC 820-10 clarifies that fair value is an exit price, representing the amount that would be received by selling an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. As a basis for considering such assumptions, FASB ASC 820-10 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:

Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.

Level 2: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.

Level 3: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.

The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

(h) Recently issued accounting pronouncements

~~ASU~~Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606)

The core principle of this new standard is that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This guidance was amended in July 2015 and is effective for annual reporting periods beginning after December 15, 2017. Adoption of this ASU did not have a material impact on the Company’s condensed consolidated financial statements.

ASU No. 2016-01, Financial Instruments – Overall (Topic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities

This standard amends various aspects of the recognition, measurement, presentation, and disclosure for financial instruments. With respect to the Company’s condensed consolidated financial statements, the most significant impact relates to the accounting for equity investments. It will impact the disclosure and presentation of financial assets and liabilities. The amendments in this update are effective for annual reporting periods, and interim periods within those years beginning after December 15, 2017. Adoption of this ASU did not have a material impact on the Company’s condensed consolidated financial statements.

ASU No. 2016-02, Leases (Topic 842)

This standard provides new guidance related to accounting for leases and supersedes ~~U.S.~~ GAAP on lease accounting with the intent to increase transparency. This standard requires operating leases to be recorded on the balance sheet as assets and liabilities and requires disclosure of key information about leasing arrangements. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the statement of operations and comprehensive loss. The adoption will require a modified retrospective approach as of the beginning of the earliest period presented. The new standard is effective for the fiscal year beginning after December 15, 2018, with early adoption permitted. The Company is currently in the process of evaluating the impact of the adoption on its condensed consolidated financial statements, ~~but the Company~~and expects that it will result in a significant increase in its long-term assets and liabilities.

ASU No. 2017-04, ~~Intangibles-Goodwill~~Intangibles – Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment

This standard provides new guidance to eliminate the requirement to calculate the implied fair value of goodwill, or the Step 2 test, to measure a goodwill impairment charge. Instead, entities will record an impairment charge based on the excess of a reporting unit’s carrying amount over its fair value. The loss recognized should not exceed the total goodwill allocated to the reporting unit. The new standard is effective for the fiscal year beginning after December 15, 2019, with early adoption permitted. The Company early adopted this standard effective January 1, 2018. Adoption of this ASU did not have a material impact on the Company’s condensed consolidated financial statements.

ASU No. 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815)

This standard provides new guidance to address the complexity of accounting for certain financial instruments with down round features. The amendments of this ASU change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. A down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. A freestanding equity-linked financial instrument (or embedded conversion feature) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. The new standard is effective for the fiscal year beginning after December 15, 2018 with early adoption permitted. The Company early adopted this standard effective January 1, 2018. Adoption of this ASU did not have a material impact on the Company’s condensed consolidated financial statements.

ASU No. 2018-02, Income Statement – Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income

This standard provides guidance on the reclassification of certain tax effects from accumulated other comprehensive income to retained earnings in the period in which the effects of the change in the United States federal corporate income tax rate in the Tax Cuts and Jobs Act is recorded. The new standard is effective for the fiscal year beginning after December 15, 2018. The Company is currently in the process of evaluating the ~~potential~~ impact of the adoption of this standard on its condensed consolidated financial statements.

ASU No. 2018-11, Leases (Topic 842): Targeted Improvements

This standard provides an optional transition method to adopt the new leases standard in Topic 842 which permits the recognition of a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The amendments do not change the existing disclosure requirements in Topic 840. The new standard is effective for the fiscal year beginning after December 15, 2018. The Company is currently in the process of evaluating the impact of the adoption on its condensed consolidated financial statements, and expects that it will result in an adjustment to the opening balance of retained earnings in the period of adoption.

ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement

This amendment provides updates to the disclosure requirements on fair value measures in Topic 820 which includes the changes in unrealized gains and losses in other comprehensive income for recurring Level 3 fair value measurements, the option of additional quantitative information surrounding unobservable inputs and the elimination of disclosures around the valuation processes for Level 3 measurements. The new standard is effective for the fiscal year beginning after December 15, 2019. The Company is currently in the process of evaluating the impact of the adoption of this standard on its condensed consolidated financial statements.

(i) Reclassification

Certain balances have been reclassified to conform to presentation requirements, including the presentation of discontinued operations and the consistent presentation of the allocation of cost of sales and general and administrative expenses between store locations and corporate in the condensed consolidated statements of operations and comprehensive loss.

Note 3. Net Loss per Share of Common Stock

The table below presents the computation of basic and diluted net ~~losses~~loss per share of ~~common stock:~~Common Stock:

Three months ended
March 31,
2018 2017
Basic numerator:
Net loss from continuing operations attributable to shares of common stock $ (23,328 ) $ (4,947 )
Net loss from discontinued operations attributable to shares of common stock (605 ) (1,478 )
Net loss attributable to the Company $ (23,933 ) $ (6,425 )
Basic denominator:
Basic shares of common stock outstanding 26,592,781 18,862,715

Basic loss per share of common stock from continuing operations $ (0.88 ) $ (0.26 )
Basic loss per share of common stock from discontinued operations (0.02 ) (0.08 )
Basic net loss per share of common stock $ (0.90 ) $ (0.34 )

Diluted numerator:
Net loss from continuing operations attributable to shares of common stock $ (23,328 ) $ (4,947 )
Net loss from discontinued operations attributable to shares of common stock (605 ) (1,478 )
Net loss attributable to the Company $ (23,933 ) $ (6,425 )
Diluted denominator:
Diluted shares of common stock outstanding 26,592,781 18,862,715

Diluted loss per share of common stock from continuing operations $ (0.88 ) $ (0.26 )
Diluted loss per share of common stock from discontinued operations (0.02 ) (0.08 )
Diluted net loss per share of common stock $ (0.90 ) $ (0.34 )

Net loss per share data presented excludes from the calculation of diluted net loss the following potentially dilutive securities, as they had an anti-dilutive impact:
Both vested and unvested options to purchase an equal number of shares of common stock of the Company 3,579,585 5,138,732
Unvested RSUs to issue an equal number of shares of common stock of the Company 330,188 400,942
Warrants to purchase an equal number of shares of common stock of the Company 3,087,500 3,430,877
Preferred stock on an as converted basis 3,364,328 3,931,416
Total number of potentially dilutive instruments excluded from the calculation of net loss per share of common stock 10,361,601 12,901,967

	Three months ended September 30,						Nine months ended September 30,
	2018			2017			2018			2017
Basic and diluted numerator:
Net loss from continuing operations attributable to shares of common stock	$	(3,187	)	$	(3,998	)	$	(29,528	)	$	(13,658	)
Net loss from discontinued operations attributable to shares of common stock		-			(699	)		(1,115	)		(4,474	)
Net loss attributable to the Company	$	(3,187	)	$	(4,697	)	$	(30,643	)	$	(18,132	)
Basic and diluted denominator:
Basic shares of common stock outstanding		28,352,284			24,144,002			27,268,792			20,852,034

Basic loss per share of common stock from continuing operations	$	(0.11	)	$	(0.16	)	$	(1.08	)	$	(0.65	)
Basic loss per share of common stock from discontinued operations		-			(0.04	)		(0.04	)		(0.22	)
Basic and diluted net loss per share of common stock	$	(0.11	)	$	(0.20	)	$	(1.12	)	$	(0.87	)

Net loss per share data presented excludes from the calculation of diluted net loss the following potentially dilutive securities, as they had an anti-dilutive impact:
Both vested and unvested options to purchase an equal number of shares of common stock of the Company		2,285,000			4,876,899			2,285,000			4,876,899
Unvested RSUs to issue an equal number of shares of common stock of the Company		455,000			365,565			455,000			365,565
Warrants to purchase an equal number of shares of common stock of the Company		14,073,390			3,087,500			14,073,390			3,087,500
Preferred stock on an as converted basis		3,364,328			3,439,587			3,364,328			3,620,626
Convertible notes on an as converted basis		4,350,000			—			4,350,000			—
Total number of potentially dilutive instruments, excluded from the calculation of net loss per share		24,527,718			11,769,551			24,527,718			11,950,590

Note 4. Goodwill

On January 5, 2018, the Company changed its name to XpresSpa Group as part of a rebranding effort to ~~align~~carry out its corporate strategy to build a pure-play health and wellness services company, which the Company commenced following its acquisition of XpresSpa on December 23, 2016. ~~Following~~The Company completed the ~~subsequent~~ sale of Group Mobile on March 22, 2018, which was the only remaining component of the Company’s technology operating ~~segment,~~segment. Following the sale of Group Mobile, the Company’s management made the decision that its intellectual property operating segment would no longer be an area of focus and would no longer ~~operate as~~be a separate operating segment as it is not expected to generate any material revenues. This completed the transition of the Company into a pure-play health and wellness company with only one operating segment, consisting of its XpresSpa business.

The Company’s market capitalization is sensitive to the volatility of its stock price. On January 2, 2018, the first trading day of ~~the~~ fiscal year 2018, the Company’s stock price opened at $1.36 and closed at $1.45. The closing price of the Company’s stock on March 29, 2018, the last trading day of the first quarter of fiscal 2018, was $0.72. The average closing stock price of the Company from January 2, 2018 through March 29, 2018 was approximately $1.02, ranging from $0.71 to $1.80 during that period.

~~Subsequent to the first quarter of fiscal 2018, on~~On April 19, 2018, the Company entered into a separation agreement with its Chief Executive Officer regarding his resignation as Chief Executive Officer and as a Director the Company. On that same date, the Company’s Senior Vice President and Chief Executive Officer of XpresSpa was appointed by the Board of Directors as the Chief Executive Officer and as a Director of the Company.

These events were identified by the Company’s management as triggering events requiring that goodwill be tested for impairment as of March 31, 2018. In addition to the Company’s rebranding efforts to a pure-play health and wellness services company, its stock price continued to decline even after the announcement of the new Chief Executive Officer. ~~The Company’s stock price has averaged $0.67 following March 31, 2018.~~ As the stock price ~~has~~had not rebounded, the Company determined that the impairment ~~relates~~related to the three-month period ended March 31, 2018.

The Company performed a quantitative goodwill impairment test, in which the Company compared the carrying value of the reporting unit to its estimated fair value, which was calculated using an income approach. The key assumptions for this approach ~~are~~were projected future cash flows and a discount rate, which iswas based on a weighted average cost of capital adjusted for the relevant risk associated with the characteristics of the business and the projected future cash flows. As a result of the quantitative goodwill impairment test performed as of March 31, 2018, the Company determined that the fair value of the reporting unit did not exceed its carrying amount and, therefore, goodwill of the reporting unit was considered impaired.

Based on the estimated fair value of goodwill, the Company recorded an impairment charge of $19,630, to reduce the carrying value of goodwill to its fair value, which was determined to be zero. This impairment charge is included in goodwill impairment in the condensed consolidated statements of operations and comprehensive loss for the ~~three-month~~nine-month period ended ~~March 31,~~September 30, 2018.

The fair value measurement of goodwill was classified within Level 3 of the fair value hierarchy because the income approach was used, which utilizes significant inputs that are unobservable in the market. The Company believes it made reasonable estimates and assumptions to calculate the fair value of the reporting unit as of the impairment test measurement date.

Note 5. Other Assets

Other assets in the condensed consolidated balance sheets are comprised of the following as of ~~March 31,~~September 30, 2018 and December 31, 2017:

	March 31, 2018		December 31, 2017		September 30, 2018		December 31, 2017
Cost method investments	$	2,909	$	834	$	2,502	$	834
Lease deposits		856		852		854		852
Other assets	$	3,765	$	1,686	$	3,356	$	1,686

As of ~~March 31,~~September 30, 2018, the Company’s other assets included:

$1,625 cost method investment in Route1 Inc. (“Route1”), which the Company received from the disposition of Group Mobile in March 2018;

$~~856 deposits made pursuant to various lease agreements, which will be returned to the Company at the end of the leases;~~

$787 cost method investment in InfoMedia Services Limited (“InfoMedia”), which the Company acquired in 2014;

$~~450~~43 cost method investment in Marathon Patent Group, Inc. (“Marathon”), ~~that~~which the Company ~~received~~acquired in January ~~2018;~~2018 with an acquisition date fair value of $450. Based on the Company’s evaluation of the investment, it was determined that certain unrealized losses represented an other-than-temporary impairment as of September 30, 2018 and the Company recognized an impairment charge of $26 and $133 for the three- and nine-month periods ended September 30, 2018, equal to the excess of carrying value over fair value. During the three-month period ended September 30, 2018, the Company sold 200,046 shares of Marathon common stock, with a carrying value of $274, for net proceeds of $193;

	·	$47 cost method investment in FLI Charge, which the Company received from the disposition of FLI Charge in October ~~2017.~~2017; and

	·	$854 deposits made pursuant to various lease agreements, which will be returned to the Company at the end of the leases.

Note 6. Segment Information

As a result of the Company’s transition to a pure-play health and wellness services company, it currently has one operating segment that is also its sole reporting unit, ~~which is comprised of~~ XpresSpa.

The Company currently operates in two geographical segments: the United States and all other countries. The following table represents the geographical revenue and segment operating loss for the ~~three-month~~three- and nine-month periods ended ~~March 31,~~September 30, 2018 and 2017 and total asset information as of ~~March 31,~~September 30, 2018 and December 31, 2017. There were no concentrations of geographical revenue, segment operating loss or total assets related to any single foreign country that were material to the Company’s condensed consolidated financial statements.

	Three months ended March 31,						Three months ended September 30,						Nine months ended September 30,
	2018			2017			2018			2017			2018			2017
Revenue
United States	$	11,259		$	9,968		$	11,516		$	11,349		$	34,513		$	32,982
All other countries		1,341			1,116			1,406			1,503			4,047			3,881
Total revenue	$	12,600		$	11,084			12,922			12,852			38,560			36,863

Cost of sales
United States	$	8,990		$	8,257			9,056			9,637			27,524			27,588
All other countries		787			677			929			836			2,597			2,338
Total cost of sales	$	9,777		$	8,934			9,985			10,473			30,121			29,926

Segment operating income (loss)
United States	$	(23,276	)	$	(4,759	)		(3,095	)		(4,052	)		(29,470	)		(13,704	)
All other countries		220			190			210			529			461			1,225
Operating loss from continuing operations		(23,056	)		(4,569	)		(2,885	)		(3,523	)		(29,009	)		(12,479	)
Other non-operating expense, net		(273	)		(75	)		(246	)		(265	)		(335	)		(566	)
Loss from continuing operations before income taxes	$	(23,329	)	$	(4,644	)	$	(3,131	)	$	(3,788	)	$	(29,344	)	$	(13,045	)

March 31,
2018 December 31,
2017
Assets
United States $ 32,567 $ 55,152
All other countries 4,224 3,642
Assets held for disposal 717 6,446
Total assets $ 37,508 $ 65,240

	September 30, 2018		December 31, 2017
Assets
United States	$	29,878	$	55,152
All other countries		2,677		3,642
Assets held for disposal		109		6,446
Total assets	$	32,664	$	65,240

Note 7. Fair Value Measurements

Derivative Warrant Liabilities

The following table presents the placement in the fair value hierarchy of derivative warrant liabilities measured at fair value on a recurring basis as of ~~March 31,~~September 30, 2018, May 17, 2018 and December 31, 2017:

May 2015 Warrants

Fair value measurement at reporting date using
Quoted prices in
active markets Significant other Significant
for identical observable unobservable
Balance assets (Level 1) inputs (Level 2) inputs (Level 3)
March 31, 2018: $ 1 $ — $ — $ 1

December 31, 2017: $ 34 $ — $ — $ 34

			Fair value measurement at reporting date using
	Balance		Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
September 30, 2018:	$	1	$	—	$	—	$	1

December 31, 2017:	$	34	$	—	$	—	$	34

May 2018 Warrants

			Fair value measurement at reporting date using
			Quoted prices in
			active markets		Significant other		Significant
			for identical		observable		unobservable
	Balance		assets (Level 1)		inputs (Level 2)		inputs (Level 3)
September 30,2018:
A Warrants	$	455	$	—	$	—	$	455
B Warrants		—		—		—		—
Total	$	455	$	—	$	—	$	455

May 17, 2018:
A Warrants	$	1,827	$	—	$	—	$	1,827
B Warrants		135		—		—		135
Total	$	1,962	$	—	$	—	$	1,962

The Company measures its derivative warrant liabilities at fair value. The derivative warrant liabilities were classified within Level 3 because they were valued using the Black-Scholes-Merton model, which utilizes significant inputs that are unobservable in the market. These derivative warrant liabilities were initially measured at fair value and are marked to market at each balance sheet date. The derivative warrant liabilities are recorded as derivative warrant liabilities in the condensed consolidated balance sheets and the revaluation of the derivative warrants liabilities is included in other non-operating income (expense) in the condensed consolidated statements of operations and comprehensive loss.

In addition to the above, the Company’s financial instruments as of ~~March 31,~~September 30, 2018 and December 31, 2017 consisted of cash and cash equivalents, trade and loan receivables, inventory, accounts payable and other current liabilities. The carrying amounts of all the aforementioned financial instruments approximate fair value because of the short-term maturities of these instruments.

The following table summarizes the changes in the Company’s derivative warrant liabilities measured at fair value using significant unobservable inputs (Level 3) during the ~~three-month period~~three- and nine-month periods ended ~~March 31,~~September 30, 2018:

December 31, 2017 $ 34
Decrease in fair value of the derivative warrant liabilities (33 )
March 31, 2018 $ 1

December 31, 2017	$	34
Issuance of warrants May 17, 2018		1,962
Decrease in fair value of the derivative warrant liabilities		(1,541	)
September 30, 2018	$	455

Valuation processes for Level 3 Fair Value Measurements

Fair value measurement of the derivative warrant liabilities falls within Level 3 of the fair value hierarchy. The fair value measurements are evaluated by management to ensure thatchanges are consistent with expectations of management based upon the sensitivity and nature of the inputs.

~~March 31,~~May 2015 Warrants

September 30, 2018:

Description	Valuation technique	Unobservable inputs	Range
Derivative warrant liabilities	Black-Scholes-Merton	Volatility		~~39.56~~70.37	%
		~~Risk free~~Risk-free interest rate		~~2.21~~2.72	%
		Expected term, in years		~~2.09~~1.59
		Dividend yield		0.00	%

December 31, 2017:

Description	Valuation technique	Unobservable inputs	Range
Derivative warrant liabilities	Black-Scholes-Merton	Volatility		39.64	%
		Risk-free interest rate		1.88	%
		Expected term, in years		2.34
		Dividend yield		0.00	%

May 2018 Warrants

September 30, 2018:

Description	Valuation technique	Unobservable inputs	Range
Derivative warrant liabilities – A Warrants	Black-Scholes-Merton	Volatility		70.93	%
		Risk-free interest rate		2.96	%
		Expected term, in years		4.63
		Dividend yield		0.00	%

Description	Valuation technique	Unobservable inputs	Range
Derivative warrant liabilities – B Warrants	Black-Scholes-Merton	Volatility		113.31	%
		Risk-free interest rate		1.91	%
		Expected term, in years		0.12
		Dividend yield		0.00	%

May 17, 2018:

Description	Valuation technique	Unobservable inputs	Range
Derivative warrant liabilities – A Warrants	Black-Scholes-Merton	Volatility		71.13	%
		Risk-free interest rate		2.98	%
		Expected term, in years		5.00
		Dividend yield		0.00	%

Description	Valuation technique	Unobservable inputs	Range
Derivative warrant liabilities – B Warrants	Black-Scholes-Merton	Volatility		72.88	%
		Risk-free interest rate		1.99	%
		Expected term, in years		0.50
		Dividend yield		0.00	%

Sensitivity of Level 3 measurements to changes in significant unobservable inputs

The inputs to estimate the fair value of the Company’s derivative warrant liabilities were the current market price of the Company’s ~~common stock,~~Common Stock, the exercise price of the derivative warrant liabilities, their remaining expected term, the volatility of the Company’s ~~common stock~~Common Stock price and the risk-free interest rate over the expected term. Significant changes in any of those inputs in isolation can result in a significant change in the fair value measurement.

Generally, an increase in the market price of the Company’s shares of ~~common stock,~~Common Stock, an increase in the volatility of the Company’s shares of ~~common stock,~~Common Stock, and an increase in the remaining term of the derivative warrant liabilities would each result in a directionally similar change in the estimated fair value of the Company’s derivative warrant liabilities. Such changes would increase the associated liability while decreases in these assumptions would decrease the associated liability. An increase in the risk-free interest rate or a decrease in the differential between the derivative warrant liabilities’ exercise price and the market price of the Company’s shares of ~~common stock~~Common Stock would result in a decrease in the estimated fair value measurement and thus a decrease in the associated liability. The Company has not declared, and does not plan to declare, dividends on its ~~common stock,~~Common Stock, and as such, there is no change in the estimated fair value of the derivative warrant liabilities due to the dividend assumption.

Marathon Common Stock

On January 11, 2018 (the “Transaction Date”), the Company entered into a Patent Rights Purchase and Assignment Agreement (the “Agreement”) with Crypto Currency Patent Holding Company LLC (the “Buyer”) and its parent company, Marathon, pursuant to which the Buyer agreed to purchase certain of the Company’s patents. As consideration for the patents, the Buyer paid $250 and Marathon issued 250,000 shares of Marathon common stock (the “Marathon Common Stock”) to the Company. The Marathon Common Stock iswas subject to a lockup period ~~commencing~~(the “Lockup Period”) which commenced on the Transaction Date and ~~ending~~ended on July 11, 2018, ~~(the “Lockup Period”).~~subject to a leak-out provision.

The Marathon Common Stock is recognized as a cost method investment and, as such, ~~must~~was required to be measured at cost on the date of acquisition, which, as of the Transaction Date, ~~approximates~~approximated fair value. The following table presents the placement in the fair value hierarchy of the Marathon Common Stock measured at fair value on a nonrecurring basis as of the Transaction Date:

			Fair value measurement at reporting date using
			Quoted prices in
			active markets		Significant other		Significant
			for identical		observable		unobservable
	Balance		assets (Level 1)		inputs (Level 2)		inputs (Level 3)
January 11, 2018	$	450	$	—	$	450	$	—

September 30, 2018	$	43	$	43	$	—	$	—

The fair value of the Marathon Common Stock was estimated by multiplying the number of shares as they become tradeable by the price per share as of the Transaction Date, information that falls within Level 1 of the fair value hierarchy, quoted prices in active markets for identical assets; however, due to the fact that the Marathon Common Stock iswas restricted during the Lockup Period, the Company applied a discount on the lack of marketability to estimate the fair value at the measurement date, which is a significant other observable input resulting in placement in Level 2 of the fair value hierarchy. The fair value of the consideration as of the Transaction Date was determined to be $450. Based on the Company’s evaluation of the investment, it was determined that certain unrealized losses represented an other-than-temporary impairment as of September 30, 2018 and the Company recognized an impairment charge of $26 and $133 for the three and nine months ended September 30, 2018, equal to the excess of carrying value over fair value. The fair value of the remaining Marathon Common Stock held as of September 30, 2018 was determined to be $43, which is included in other assets in the condensed consolidated balance sheet as of September 30, 2018.

On July 11, 2018, the Lockup Period concluded and the Company was permitted to begin trading the Marathon Common Stock, subject to a leak-out provision whereby the shares were released from lockup in equal increments over a twenty-day period. As of September 30, 2018, the remaining 49,954 shares of Marathon Common Stock were no longer restricted pursuant to the Lockup Period and leak-out provision, and the Company determined that the investments are classified within Level 1 of the fair value hierarchy.

During the three-month period ended September 30, 2018, the Company sold 200,046 shares of Marathon common stock, with a carrying value of $274, for net proceeds of $193.

The following table summarizes the changes in the Company’s investment in Marathon Common Stock, measured at fair value using significant other observable inputs (Level 2) as of Transaction Date and measured at fair value using quoted prices in active markets for identical assets (Level 1) during the three- and nine-month periods ended September 30, 2018:

January 11, 2018	$	450
Carrying value of Marathon Common Stock sold		(274	)
Decrease in fair value of the Marathon Common Stock		(133	)
September 30, 2018	$	43

Other Fair Value Measurements

The Company is also required to measure the fair value ~~on a recurring basis~~ of the contingent consideration it assumed following the acquisition of Excalibur Integrated Systems, Inc. (“Excalibur”) on February 2, ~~2017.~~2017 on a recurring basis. The Company determined that there was no change in the fair value of the contingent consideration of $316 between December 31, 2017 and ~~March 31,~~September 30, 2018. Although the Company disposed of Excalibur as part of the Group Mobile disposition, the contingent consideration remained due to the remnant of the earn-out provision due to the former stockholders of Excalibur, which is what first led to the recognition of a contingent consideration upon the acquisition of Excalibur. The contingent consideration is included in other liabilities in the condensed consolidated balance sheets.

The purchase value of the contingent consideration assumed by the Company following the acquisition of Excalibur was determined using the Monte-Carlo simulation and, as such, was classified in Level 3 of the fair value hierarchy. The fair value measurements are evaluated by management to ensure that changes are consistent with expectations of management based upon the sensitivity and nature of the inputs.

Note 8. Stock-Based Compensation

As of ~~March 31,~~September 30, 2018, ~~2,796,386~~3,358,470 shares of the Company’s ~~common stock~~Common Stock were available for future grants under the Company’s 2012 Employee, Director and Consultant Equity Incentive Plan. Total stock-based compensation expense for the three-month periods ended ~~March 31,~~September 30, 2018 and 2017 was ~~$312~~$194 and ~~$741,~~$706, respectively, the latter of which included stock-based compensation expense of ~~$194~~$44 included in discontinued operations. Total stock-based compensation expense for the nine-month periods ended September 30, 2018 and 2017 was $765 and $2,179, respectively, the latter of which included stock-based compensation expense of $427 included in discontinued operations.

The following table summarizes the RSUs granted to ~~a consultant~~employees and consultants during the ~~three-month~~nine-month period ended ~~March 31,~~September 30, 2018.

Grant date No. of RSUs
Fair market
value at grant date
Vesting term
February 28, 2018 53,408 $ 0.94 Vesting immediately upon grant

Grant date	No. of RSUs		Fair market value at grant date		Vesting term
February 28, 2018		53,408	$	0.94	Vesting immediately upon grant
April 19, 2018		150,000	$	0.60	Vesting immediately upon grant
May 15, 2018		465,000	$	0.60	Over one year, vesting on one-year anniversary of grant date

No options were granted during the ~~three-month~~nine-month period ended ~~March 31,~~September 30, 2018.

The activity related to RSUs and stock options during the ~~three-month~~nine-month period ended ~~March 31,~~September 30, 2018 consisted of the following:

	RSUs					Options									RSUs					Options
	No. of RSUs			Weighted average grant date fair value		No. of options			Weighted average exercise price		Exercise price range		Weighted average grant date fair value		No. of RSUs			Weighted average grant date fair value		No. of options			Weighted average exercise price		Exercise price range		Weighted average grant date fair value
Outstanding as of January 1, 2018		365,565		$	2.12		4,317,942		$	5.67	$	1.10 – 41.00	$	3.86		365,565		$	2.12		4,317,942		$	5.67	$	1.10 – 41.00	$	3.86
Granted		53,408		$	0.94		—			—		—		—		668,408		$	0.63		—			—		—		—
Vested/Exercised		(88,785	)	$	1.41		—			—		—		—		(568,973	)	$	1.61		—			—		—		—
Forfeited		—			—		(686,041	)	$	7.99	$	1.55 – 37.20	$	5.40		(10,000)		$	0.60		(1,980,625	)	$	6.17	$	1.55 – 37.20	$	4.11
Expired		—			—		(52,316	)	$	16.24	$	9.60 – 16.50	$	9.71		—			—		(52,317	)	$	16.24	$	9.60 – 16.50	$	9.71
Outstanding as of March 31, 2018		330,188		$	2.12		3,579,585		$	5.07	$	1.10 – 41.00	$	3.39
Exercisable as of March 31, 2018		—			—		2,505,417		$	6.45	$	1.10 – 41.00
Outstanding as of September 30, 2018																455,000		$	0.60		2,285,000		$	4.99	$	1.10 – 41.00	$	3.12
Exercisable as of September 30, 2018																—			—		1,905,834		$	5.59	$	1.10 – 41.00	$	3.53

The Company did not recognize tax benefits related to its stock-based compensation as there is a full valuation allowance recorded.

Note 9. Debt and Convertible Notes

Debt

On April 22, 2015, prior to the acquisition of XpresSpa, XpresSpa entered into a credit agreement and secured promissory note (the “Debt”) with Rockmore Investment Master Fund Ltd. (“Rockmore”), a related party, which was amended on August 8, 2016 in connection with the Company’s acquisition of XpresSpa. Rockmore is an investment entity controlled by the Company’s Chairman of the Board of Directors, Bruce T. Bernstein. The Debt had an outstanding balance of $6,500 as of September 30, 2018 and December 31, 2017, which is included in long-term liabilities in the condensed consolidated balance sheets. During the nine-month period ended September 30, 2018, XpresSpa paid $580 of interest and recorded $548 of interest expense related to the debt.

On May 14, 2018, the Company and Rockmore agreed to extend the maturity date of the Debt from May 1, 2019 to December 31, 2019. No other material terms of the Debt were modified. As consideration for the agreement to extend the maturity date of the Debt and the consent to the Securities Purchase Agreement, the Company issued to Rockmore 250,000 Class A Warrants. These Class A Warrants were issued on the same terms and conditions as the Class A Warrants issued under the Securities Purchase Agreement. The warrants issued to Rockmore were classified as equity warrants in the condensed consolidated balance sheet as of September 30, 2018.

Convertible Notes

On May 15, 2018, the Company entered into the Securities Purchase Agreement with the Investors, pursuant to which the Company agreed to sell up to (i) an aggregate principal amount of $4,438 in the Convertible Notes, which includes $88 issued to Palladium Capital Advisors as Placement Agent, convertible into Common Stock at a conversion price of $0.62 per share, (ii) Class A Warrants to purchase 7,157,259 shares of Common Stock at an exercise price of $0.62 per share and (iii) Class B Warrants to purchase up to 3,578,630 shares of Common Stock at an exercise price of $0.62 per share. The Convertible Notes bear interest at a rate of 5% per annum. The Convertible Notes are senior secured obligations of the Company and are secured by certain of its personal property. Unless earlier converted or redeemed, the Convertible Notes will mature on November 16, 2019. The transaction closed on May 17, 2018.

The principal amount of the outstanding Convertible Notes is to be repaid monthly in the amount of $296, beginning on September 17, 2018, and the Company may make such payments and related interest payments in cash or, subject to certain conditions, in registered shares of Common Stock (or a combination thereof), at its election. If the Company chooses to repay the Convertible Notes in shares of Common Stock, the shares will be issued at a 10% discount to the volume weighted average price of Common Stock for the five (5) trading days commencing eight (8) days prior to the relevant repayment date and ending on the fourth (4^th) trading day prior to such repayment date, subject to a minimum floor price of not less than 20% of the conversion price of the Convertible Notes on the issue date. The Company may also repay the Convertible Notes in advance of the maturity schedule subject to an early repayment penalty of 15%.

On August 14, 2018, the Company and each of the Investors entered into an Amendment Agreement (“Amendment Agreement”) whereby the initial monthly principal repayment and accrued interest due on the Convertible Notes of $351 was settled in 2,067 shares of Common Stock on August 15, 2018. All other material terms of the Securities Purchase Agreement remained unchanged. During the three-month period ended September 30, 2018, several of the Investors converted their monthly principal payments and accrued interest due on the Convertible Notes into shares of Common Stock pursuant to the Amendment Agreement, resulting in the issuance of an additional 2,737 shares of Common Stock.

The table below summarizes the initial fair value of the Convertible Notes and Warrants as of May 17, 2018:

Class A Warrants	$	1,827
Class B Warrants		135
Convertible Notes		2,388
Total Fair Value	$	4,350

The table below summarizes changes in the book value of the Convertible Notes from May 17, 2018 to September 30, 2018:

Book value as of May 17, 2018	$	2,388
Debt issuance costs		(320	)
Book value as of May 17, 2018		2,068
Debt repayments in the period		(649	)
Amortization of debt discount and debt issuance costs, included in interest expense		589
Book value as of September 30, 2018	$	2,008

The debt discount and debt issuance costs will be amortized on a straight-line basis over the remaining term of the Convertible Notes. During the three- and nine-month periods ended September 30, 2018, the Company recorded $394 and $589 of amortization of debt discount and debt issuance costs, which was included in interest expense for the three- and nine-month periods ended September 30, 2018. Additionally, for the three- and nine-month periods ended September 30, 2018, the Company recorded $48 and $75 of interest expense related to the Convertible Notes, which was included in interest expense.

Note 9.10. Related Party Transactions

On April 22, 2015, XpresSpa entered into a credit agreement and secured promissory note (the “Debt”) with Rockmore Investment Master Fund Ltd. (“Rockmore”), which was amended on August 8, 2016. Rockmore is an investment entity controlled by the Company’s board member, Bruce T. Bernstein. The Debt had an outstanding balance of $6,500 as of March 31, 2018 and December 31, 2017, included in long-term liabilities in the condensed consolidated balance sheets. During the quarter ended March 31, 2018, XpresSpa paid $150 of interest and recorded $183 of interest expense related to the debt.

On ~~May~~April 14, 2018, the Company ~~and Rockmore agreed to extend the maturity date~~entered into a consulting agreement with an employee of Mistral Equity Partners, which is a significant shareholder of the ~~Debt from May 1, 2019~~Company and whose Chief Executive Officer is a member of the Board of Directors of the Company, to consult on certain business-related matters. The total consideration is approximately $10 per month through December 31, ~~2019. No other material terms~~2018. The agreement may be terminated by either party at any time upon delivery of written notice. Pursuant to the ~~Debt were modified.~~agreement, the Company recorded consulting expense of $30 and $55 for the three- and nine-month periods ended September 30, 2018, respectively.

Note ~~10.~~11. Discontinued Operations and Assets and Liabilities Held for Disposal

FLI Charge

On October 20, 2017, the Company sold FLI Charge to a group of private investors and FLI Charge management, to own and operate FLI Charge. Post-closing, the Company does not provide any continued management or financing support to FLI Charge.

Group Mobile

On March 7, 2018 (the “Signing Date”), the Company entered into a membership purchase agreement (the ~~“Purchase~~“Group Mobile Purchase Agreement”) with Route1 Security Corporation, a Delaware corporation (the “Buyer”), and Route1 pursuant to which the Buyer agreed to acquire Group Mobile (the “Disposition”). The transaction closed on March 22, 2018 (the “Closing Date”), after which the Company no longer had any involvement with Group Mobile.

In consideration for the Disposition, the Buyer issued to the Company:

25,000,000 shares of Route1 ~~common stock~~Common Stock (the “Route1 Common Stock”);

warrants to purchase 30,000,000 shares of Route1 Common Stock, which will feature an exercise price of CAD 5 cents per share of ~~common stock~~Common Stock and will be exercisable for a three-year period; and

certain other payments over the three-year period pursuant to an earn-out provision in the Group Mobile Purchase Agreement.

The Company retained certain inventory with a value of $555 to be disposed of separately from the transaction with Route1 in the first half of 2018. Of this amount, $110 was sold as of ~~March 31, 2018 resulting in $445~~June 30, 2018. The remaining ~~in assets held for disposal in~~inventory excluded from the ~~condensed consolidated balance sheets~~transaction was subsequently determined to be obsolete and unsalable and was fully written off as of ~~that date.~~June 30, 2018. Assets held for disposal ~~also~~ includes ~~$272~~$109 of accounts receivable, net of allowance, associated with the sale of the inventory excluded from the transaction with Route1.

Post-closing, the Company owned approximately 6.7% of Route1 Common Stock. The Route1 Common Stock is not tradable until a date no earlier than 12 months after the Closing Date; 50%, or 12,500,000 shares, of Route1 Common Stock are tradeable after 12 months plus an additional 2,083,333 shares of Route1 Common Stock are tradeable each month until 18 months after the Closing Date, subject to a change of control provision. The Company has the ability to sell the Route1 Common Stock and warrants to qualified institutional investors. The Group Mobile Purchase Agreement also contains representations, warranties, and covenants customary for transactions of this type.

The total consideration of the Disposition is recognized as a cost method investment and, as such, must be measured at cost on the date of acquisition, which, as of the Closing Date, approximates fair value. The fair value of the total consideration as of the Closing Date was determined to be $1,625, which is less than the carrying value of the asset, and is included in other assets in the condensed consolidated balance sheet as of ~~March 31,~~September 30, 2018. This resulted in a loss on disposal of $301, which is included in consolidated net loss from discontinued operations in the condensed consolidated ~~statements~~statement of operations and comprehensive ~~loss.~~loss for the nine-month period ended September 30, 2018.

The value of the total consideration for the Group Mobile disposition was determined using a combination of valuation methods including:

(i)

The value of the Route 1 Common Stock was determined to be $308, which was estimated by multiplying the number of shares as they become tradeable by the price per share as of the Closing Date.

(ii)

The value of the warrants was determined to be $176, which was obtained using the Black-Scholes-Merton model.

(iii)

The value of the earn-out provision was determined to be $1,141, which was estimated using a Monte-Carlo simulation analysis.

The value of the Route1 Common Stock was classified within Level 2 of the fair value hierarchy because, although quoted prices in active markets for identical assets were used, which is a Level 1 attribute, the Company applied a discount on the lack of marketability to estimate the fair value due to the fact that the Route1 Common Stock will be restricted for different periods, which is a significant other observable input. The value of the warrants and earn-out provision were classified within Level 3 of the fair value hierarchy because they were valued using the Black-Scholes-Merton model and a ~~Mote-Carlo~~Monte-Carlo simulation analysis, respectively, each of which utilizes significant inputs that are unobservable in the market.

The Company’s fair value measurements are evaluated by management to ensure that they are consistent with expectations of management based upon the sensitivity and nature of the inputs.

Operating Results and Assets and Liabilities Held for Sale

The following table presents the components of the consolidated net loss from discontinued operations, as presented in the condensed consolidated statements of operations and comprehensive loss, for the ~~three-month~~three- and nine-month periods ended ~~March 31,~~September 30, 2018 for Group Mobile and ~~March 31,~~September 30, 2017 for Group Mobile and FLI Charge:

Three months ended March 31,
2018 2017
Revenue $ 2,834 $ 3,525
Cost of sales (2,305 ) (2,960 )
Depreciation and amortization (131 ) (173 )
General and administrative (680 ) (1,868 )
Loss on disposal (301 ) —
Non-operating expense (22 ) (2 )
Loss from discontinued operations before income taxes (605 ) (1,478 )
Income tax expense — —
Consolidated net loss from discontinued operations $ (605 ) $ (1,478 )

	Three months ended September 30,					Nine months ended September 30,
	2018		2017			2018			2017
Revenue	$	—	$	4,889		$	2,834		$	11,883
Cost of sales		—		(3,918	)		(2,305	)		(9,603	)
Depreciation and amortization		—		(196	)		(131	)		(568	)
Impairment		—		—			—			(1,092	)
General and administrative		—		(1,463	)		(1,190	)		(5,079	)
Loss on disposal		—		—			(301	)		—
Non-operating income (expense), net		—		(11	)		(22	)		(15	)
Loss from discontinued operations before income taxes		—		(699	)		(1,115	)		(4,474	)
Income tax benefit (expense)		—		—			—			—
Consolidated net loss from discontinued operations	$	—	$	(699	)	$	(1,115	)	$	(4,474	)

In addition, the following table presents the carrying amounts of Group Mobile’s major classes of assets and liabilities held for disposal as of ~~March 31,~~September 30, 2018 and December 31, 2017, as presented in the condensed consolidated balance sheets:

	March 31, 2018		December 31, 2017		September 30, 2018		December 31, 2017
Cash	$	—	$	150	$	—	$	150
Accounts receivable, net		272		2,920		109		2,920
Inventory		445		1,935		—		1,935
Other current assets		—		3		—		3
Property and equipment, net		—		874		—		874
Intangible assets, net		—		564		—		564
Assets held for disposal	$	717	$	6,446	$	109	$	6,446

Accounts payable, accrued expenses and other current liabilities	$	—	$	3,142	$	40	$	3,142
Deferred revenue		—		619		—		619
Liabilities held for disposal	$	—	$	3,761	$	40	$	3,761

Note ~~11.~~12. Income Taxes

The Company’s provision for income taxes consists of federal, state, local, and foreign taxes in amounts necessary to align the Company’s year-to-date provision for income taxes with the effective tax rate that the Company expects to achieve for the full year. Each quarter, the Company updates its estimate of the annual effective tax rate and records cumulative adjustments as deemed necessary. The income tax provisions for the ~~quarter~~nine-month period ended ~~March 31,~~September 30, 2018 reflect an estimated global annual effective tax rate of approximately ~~0.57%~~0.44%.

As of ~~March 31,~~September 30, 2018, deferred tax assets generated from the Company’s activities in the United States were offset by a valuation allowance because realization depends on generating future taxable income, which, in the Company’s estimation, is not more likely than not to be generated before such net operating loss carryforwards expire. Net operating losses generated for tax years beginning after December 31, 2017 do not expire. The Company expects its effective tax rate for its current fiscal year to be significantly lower than the statutory rate as a result of a full valuation allowance; therefore, any loss before income taxes does not generate a corresponding income tax benefit.

Income tax benefit for the ~~quarter~~nine-month period ended ~~March 31,~~September 30, 2018 of ~~$84~~$198 was attributable primarily to the reduction to the valuation allowance as a result of the Tax Cuts and Jobs Act’s impact on the lives of net operating losses. The final annual tax rate cannot be determined until the end of the fiscal year; therefore, the actual tax rate could differ from current estimates. Although the Company has an immaterial amount of uncertain tax positions, the Company does not expect to record any additional material provisions for unrecognized tax benefits in the next year.

Note ~~12.~~13. Commitments and Contingencies

Litigation and legal proceedings

Certain of the Company’s outstanding legal matters include speculative claims for substantial or indeterminate amounts of damages. The Company regularly evaluates developments in its legal matters that could affect the amount of any potential liability and makes adjustments as appropriate. Significant judgment is required to determine both the likelihood of there being a liability and the estimated amount of a loss related to such matters.

With respect to the Company’s outstanding legal matters, based on its current knowledge, the Company’s management believes that the amount or range of a potential loss will not, either individually or in the aggregate, have a material adverse effect on its business, consolidated financial position, results of operations or cash flows. However, the outcome of such legal matters is inherently unpredictable and subject to significant uncertainties. The Company evaluated the matters described below and assessed the probability and likelihood of the occurrence of liability. Based on management’s estimates, the Company ~~recorded $250,~~has accrued $290 for such potential losses, which is included in accounts payable, accrued expenses, and other current liabilities in the condensed consolidated balance sheet as of ~~March 31,~~September 30, 2018.

The Company expenses legal fees in the period in which they are incurred.

Cordial

Effective October 2014, XpresSpa terminated its former Airport Concession Disadvantaged Business Enterprise (“ACDBE”) partner, Cordial Endeavor Concessions of Atlanta, LLC (“Cordial”), in several store locations at Hartsfield-Jackson Atlanta International Airport.

Cordial filed a series of complaints with the City of Atlanta, both before and after the termination, in which Cordial alleged, among other things, that the termination was not valid and that XpresSpa unlawfully retaliated against Cordial when Cordial raised concerns about the joint venture. In response to the numerous complaints it received from Cordial, the City of Atlanta required the parties to engage in two mediations.

After the termination of the relationship with Cordial, XpresSpa sought to substitute two new ACDBE partners in place of Cordial.

In April 2015, Cordial filed a complaint with the United States Federal Aviation Administration (“FAA”), which oversees the City of Atlanta with regard to airport ACDBE programs, and, in December 2015, the FAA instructed that the City of Atlanta review XpresSpa’s request to substitute new partners in lieu of Cordial and Cordial’s claims of retaliation. In response to the FAA instruction, pursuant to a corrective action plan approved by the FAA, the City of Atlanta held a hearing in February 2016 and ruled in favor of XpresSpa such substitution and claims of retaliation. Cordial submitted a further complaint to the FAA claiming that the City of Atlanta was biased against Cordial and that the City of Atlanta’s decision was wrong. In August 2016, the parties met with the FAA. On October 4, 2016, the FAA sent a letter to the City of Atlanta directing that the City of Atlanta retract previous findings on Cordial’s allegations and engage an independent third party to investigate issues previously decided by Atlanta. The FAA also directed that the City of Atlanta determine monies potentially due to Cordial.

On January 3, 2017, XpresSpa filed a lawsuit in the Supreme Court of the State of New York, County of New York, against Cordial and several related parties. The lawsuit alleges breach of contract, unjust enrichment, breach of fiduciary duty, fraudulent inducement, fraudulent concealment, tortious interference, and breach of good faith and fair dealing. XpresSpa is seeking damages, declaratory judgment, rescission/termination of certain agreements, disgorgement of revenue, fees and costs, and various other relief. On February 21, 2017, the defendants filed a motion to dismiss. On March 3, 2017, XpresSpa filed a first amended complaint against the defendants. On April 5, 2017, Cordial filed a motion to dismiss. On September 12, 2017, the Court held a hearing on the motion to dismiss. On November 2, 2017, the Court granted the motion to dismiss which was entered on November 13, 2017. On December 22, 2017, XpresSpa filed a notice of ~~appeal.~~appeal, and on September 24, 2018, XpresSpa perfected its appellate rights and submitted a brief to the Supreme Court of New York, First Department appellate court. Oral arguments on the appeal are expected to take place in early 2019.

On March 30, 2018, Cordial filed a lawsuit against XpresSpa, a subsidiary of XpresSpa, and several additional parties in the Superior Court of Fulton County, Georgia, alleging the violation of Cordial’s civil rights, tortious interference, breach of fiduciary duty, civil conspiracy, conversion, retaliation, and unjust enrichment. Cordial has threated to seek punitive damages, attorneys’ fees and litigation expenses, accounting, indemnification, and declaratory judgment as to the status of the membership interests of XpresSpa and Cordial in the joint venture and Cordial’s right to profit distributions and management fees from the joint venture. On May 3, 2018, the Court issued an order extending the time for the defendants to respond to Cordial’s lawsuit until June 25, 2018. On May 4, 2018, the defendants ~~removed~~moved the lawsuit to the United States District Court for the Northern District of Georgia. On June 5, 2018, the Court granted an extension of time for the defendants’ response until August 17, 2018. On August 9, 2018, the Court granted an additional extension of time for the defendants’ response until September 7, 2018, and thereafter provided another extension pending the Court’s consideration of XpresSpa’s Motion to Stay all action in the Georgia lawsuit, pending resolution of the New York lawsuit and the FAA action. On October 29, 2018, XpresSpa’s Motion to Stay was denied. XpresSpa and other defendants are now preparing motions to dismiss the amended complaint, and such motions are due on November 20, 2018.

In re Chen et al.

In March 2015, four former XpresSpa employees who worked at XpresSpa locations in John F. Kennedy International Airport and LaGuardia Airport filed a putative class and collective action wage-hour litigation in the United States District Court, Eastern District of New York. In re Chen et al., CV 15-1347 (E.D.N.Y.). Plaintiffs claim that they and other spa technicians around the country were misclassified as exempt commissioned salespersons under Section 7(i) of the federal Fair Labor Standards Act (“FLSA”). Plaintiffs also assert class claims for unpaid overtime on behalf of New York spa technicians under the New York Labor Law, and discriminatory employment practices under New York State and City laws. On July 1, 2015, the plaintiffs moved to have the court authorize notice of the FLSA misclassification claim sent to all employees in the spa technician job classification at XpresSpa locations around the country in the last three years. Defendants opposed the motion. On February 16, 2016, the Magistrate Judge assigned to the case issued a Report & Recommendation, recommending that the District Court Judge grant the plaintiffs’ motion. On March 1, 2016, the defendants filed Opposition to the Magistrate Judge’s Report & Recommendation, arguing that the District Court Judge should reject the Magistrate Judge’s findings. On September 23, 2016, the court ruled in favor of the plaintiffs and conditionally certified the class. The parties held a mediation on February 28, 2017 and reached an agreement on a settlement in principle. On September 6, 2017, the parties entered into a settlement agreement. On September 15, 2017, the parties filed a motion for settlement approval with the Court. XpresSpa subsequently paid the agreed-upon settlement amount to the settlement claims administrator to be held in escrow pending a fairness hearing and final approval by the Court. On March 30, 2018 the Court entered a Memorandum and Order denying the motion without prejudice to renewal due to questions and concerns the Court had about certain settlement terms. On April 24, 2018 the parties jointly submitted a supplemental letter to the Court advocating for the fairness and adequacy of the settlement, and we appeared in Court on April 25, 2018 for a hearing to discuss the settlement terms in greater detail with the assigned Magistrate Judge. At the conclusion of the hearing, the Court still had questions about the adequacy and fairness of the settlement terms, and the Judge asked that the parties jointly submit additional information to the Court addressing the open issues. The parties ~~are in the process of preparing this submission for filing with~~submitted such information to the Court ~~by the~~on May 18, 2018 ~~deadline.~~and are awaiting the Court’s ruling on the open issues.

Binn v. FORM Holdings Corp. et al.

On November 6, 2017, Moreton Binn and Marisol F, LLC, former stockholders of XpresSpa, filed a lawsuit against the Company and its directors in the United States District Court for the Southern District of New York. The lawsuit alleges violations of various sections of the Exchange Act, material omissions and misrepresentations (negligent and fraudulent), fraudulent omission, expropriation, breach of fiduciary duties, aiding and abetting, and unjust enrichment in the defendants’ conduct related to the Company’s acquisition of XpresSpa, and seeks rescission of the transaction, damages, equitable and injunctive relief, fees and costs, and various other relief. On January 17, 2018, the defendants filed a motion to dismiss the complaint. On February 7, 2018, the plaintiffs amended their complaint. On February 28, 2018, the defendants filed a motion to dismiss the amended complaint. On March 21, 2018, the plaintiffs filed an opposition to the motion to dismiss the amended complaint. On March 30, 2018, the defendants filed a reply in further support of the defendants’ motion to dismiss the amended complaint. On August 7, 2018, the Court ruled on the defendants’ motion to dismiss the amended complaint, dismissing eight of the plaintiffs’ ten claims and denying the defendants’ motion to dismiss with respect to the two remaining claims, related to the Exchange Act.

Route1

On May 23, 2018, Route1 and Group Mobile filed a Statement of Claim against the Company in the Ontario (Canada) Superior Court of Justice seeking monetary damages based on indemnity claims made by Route1 and Group Mobile pursuant to the Group Mobile Purchase Agreement, including an offset against funds payable to the Company by Route1 and Group Mobile pursuant to the Group Mobile Purchase Agreement. On August 13, 2018, the Company filed its Defence and Counterclaim, seeking the payment of such funds payable to the Company by Route1 and Group Mobile pursuant to the Group Mobile Purchase Agreement.

In addition to those matters specifically set forth herein, the Company and its subsidiaries are involved in various other claims and legal actions that arise in the ordinary course of business. The Company does not believe that the ultimate resolution of these actions will have a material adverse effect on the Company’s financial position, results of operations, liquidity, or capital resources. However, a significant increase in the number of these claims, or one or more successful claims under which the Company incurs greater liabilities than the Company currently anticipates, could materially adversely affect the Company’s business, financial condition, results of operations and cash flows.

In the event that an action is brought against usthe Company or one of ~~our~~its subsidiaries, wethe Company will investigate the allegation and vigorously defend ~~ourselves.~~itself.

Intellectual Property

The Company is engaged in litigation related to certain of the intellectual property that it owns, for which no liability is recorded, as the Company does not expect a material negative outcome.

Note ~~13.~~14. Subsequent Events

Collaboration Agreement

On ~~May 15,~~November 12, 2018, the Company entered into a Product Sale and Marketing Agreement (the “Collaboration Agreement”) with Calm.com, Inc. (“Calm”) primarily related to the display, marketing, promotion, offer for sale and sale of Calm’s products in each of the Company’s branded stores throughout the United States.

The Collaboration Agreement shall remain in effect until July 31, 2019, unless terminated earlier in accordance with the ~~Investors,~~Collaboration Agreement, and automatically renew for successive terms of six (6) months unless either party provides written notice of termination no later than thirty (30) days prior to any such automatic renewal of the Collaboration Agreement.

The foregoing description of the Collaboration Agreement is only a summary and is qualified in its entirety by reference to the Collaboration Agreement. The Company intends to file a copy of the Collaboration Agreement as exhibit to its Annual Report on Form 10-K for its fiscal year ending December 31, 2018, portions of which will be subject to a FOIA Confidential Treatment Request which will be submitted to the Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. The omitted material will be included in the request for confidential treatment.

Stock Purchase Agreement

In connection with the entry into the Collaboration Agreement, the Company entered into a stock purchase agreement (the “Purchase Agreement”) with Calm, pursuant to which the Company ~~agreed~~issued to ~~sell up to (i)~~Calm an aggregate ~~principal amount~~ of ~~$4,438 in~~645,161 shares of the Company’s newly designated Series E Convertible ~~Notes,~~Preferred Stock, par value $0.01 per share (the “Series E Preferred Stock”), which ~~includes $88 issued to Palladium Capital Advisors as Placement Agent,~~is initially convertible into 3,225,806 shares of the Company’s Common Stock, par value $0.01 per share (the “Common Stock”) at a conversion price of $0.62 per share, subject to certain adjustments. The purchase price per share of the Series E Preferred Stock was $3.10 per share for gross proceeds to the Company of $2,000,000. In addition, on or before December 31, 2018 and subject to the satisfaction of the conditions under the Purchase Agreement, the Company shall sell, and Calm shall purchase, 322,581 additional shares of Series E Preferred Stock (the “Additional Series E Shares”), which will initially be convertible into 1,612,905 shares of the Company’s Common Stock at a conversion price of $0.62 per share, ~~(ii) Class A Warrants~~subject to ~~purchase 7,157,259~~certain adjustments, for gross proceeds to the Company of $1,000,000, which sale of Additional Series E Shares shall be on the same terms and conditions as those contained in the Purchase Agreement.

Series E Preferred Stock

On November 12, 2018, the Company filed with the Secretary of State of the State of Delaware a Certificate of Designation of Preferences, Rights and Limitations of Series E Convertible Preferred Stock (the “Certificate of Designations”). Pursuant to the Certificate of Designations, the holders of the Series E Preferred Stock are entitled, among other things, to an aggregate initial liquidation preference of $2,000,000 ($3,000,000 if the Second Closing occurs) and the right to participate in any dividends and distributions paid to common stockholders on an as-converted basis. The Series E Preferred Stock will vote on an as-converted basis. The Series E Preferred Stock is convertible at any time and from time to time without the payment of additional consideration and has a stated value of $3.10 per share of Series E Preferred Stock. In the event of any liquidation or dissolution of the Company, the Series E Preferred Stock ranks senior to any other class of preferred stock and to the Common Stock in the distribution of assets, to the extent legally available for distribution.

Upon the occurrence of certain fundamental events, the holders of the Series E Preferred Stock will be able to require the Company to redeem the shares of Series E Preferred Stock at the greater of the liquidation preference and the amount per share as would have been payable had the shares of Series E Preferred Stock been converted into Common Stock.

The principal amount of the outstanding Convertible Notes is to be repaid monthly in the amount of $296, beginning in September 2018, and the Company may make such payments and related interest payments in cash or, subject to certain conditions, in registered shares of its common stock (or a combination thereof), at its election. If the Company chooses to repay the Convertible Notes in shares of its common stock, the sharesdeliverable (the “Base Shares”) will be ~~issued at a 10% discount to~~based on the volume weighted average price (the “VWAP”) per share of ~~the Company’s common stock~~Common Stock for the ~~five (5)~~thirty (30) trading ~~days commencing eight (8)~~ days prior to the ~~relevant repayment~~ date of calculation (the “Base Price”) plus an additional number of shares of Common Stock (the “Premium Shares”), calculated as follows: (i) if the Base Price is greater than $9.00, no Premium Shares shall be issued, (ii) if the Base Price is greater than $7.00 and ~~ending on the fourth (4~~^th~~) trading day prior~~equal to ~~such repayment date, subject to a minimum floor price of not~~or less than $9.00, an additional number of shares equal to 5% of the Base Shares shall be issued, (iii) if the Base Price is greater than $6.00 and equal to or less than $7.00, an additional number of shares equal to 10% of the Base Shares shall be issued, (iv) if the Base Price is greater than $5.00 and equal to or less than $6.00, an additional number of shares equal to 20% of the ~~conversion~~Base Shares shall be issued and (v) if the Base Price is less than or equal to $5.00, an additional number of shares equal to 25% of the Base Shares shall be issued. Accordingly, if the volume weighted average price per share of Common Stock is below $9.00 per share at the time of repayment and the Company exercises the option to make such repayment in shares of Common Stock, a large number of shares of Common Stock may be issued to the holders of Series E Preferred Stock upon maturity, which may have a negative effect on the trading price of Common Stock. At the seven (7) year maturity date of the Series E Preferred Stock, the Company, at its election, may decide to issue shares of Common Stock based on the formula set forth above or to re-pay in cash all or any portion of the Series E Preferred Stock. However, in no event, shall the VWAP per share of Common Stock be determined to be less than $0.62.

In 2025, upon the maturity date of the Series E Preferred Stock, when determining whether to repay the Series E Preferred Stock in cash or shares of Common Stock, the Company expects to consider a number of factors, including its cash position, the price of the Common Stock and the Company’s capital structure at such time. Because the Company does not have to make a determination as to which option to elect until 2025, it is impossible to predict whether it is more or less likely to repay in cash, stock or a portion of each.

In addition, the Series E Preferred Stock contains certain protective provisions that limit the Company’s ability to make certain cash distributions or payment of any indebtedness without the written consent of the holders of a majority of the outstanding shares of Series E Preferred Stock.

The offering is exempt from registration pursuant to the exemption for transactions by an issuer not involving any public offering under Section 4(a)(2) the Securities Act and Regulation D under the Securities Act.

The shares of Series E Preferred Stock sold and issued in connection with the Purchase Agreement are not registered under the Securities Act or any state securities laws and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from the registration requirements.

Seniority to Series D Convertible ~~Notes on~~Preferred Stock

In connection with the ~~issue date.~~entry into the Purchase Agreement, a majority of the holders of the Company’s Series D Convertible Preferred Stock (the “Series D Preferred Stock”) agreed to waive the provisions of the Certificate of Designation of Preferences, Rights and Limitations of Series D Convertible Preferred Stock prohibiting any class of stock existing senior to the Series D Preferred Stock with respect to right of participation in any dividends and distributions. Upon the issuance of the issuance of the Series E Preferred Stock, the Series D Preferred Stock will rank junior to the Series E Preferred Stock with respect to the Series E Preferred Stock’s initial liquidation preference and in right of participation in any dividends and distributions.

Certificate of Designation

On November 13, 2018, the Company filed the Certificate of Designations with the Secretary of State of the State of Delaware, establishing and designating the rights, powers and preferences of the Series E Preferred Stock. The Company ~~may also repay the Convertible Notes in advance~~designated up to 1,473,300 shares of Series E Preferred Stock.

The foregoing summaries of the ~~maturity schedule subject~~Purchase Agreement and Certificate of Designations do not purport to ~~early repayment penalties~~be complete and are qualified in their entirety by reference to the Purchase Agreement and Certificate of ~~15%.~~Designations, which are attached hereto as Exhibits 10.1 and 3.1, respectively, to this Quarterly Report on Form 10-Q and are incorporated by reference herein.

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations.

This Quarterly Report on Form 10-Q contains “forward-looking statements” that involve risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The statements contained herein that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are often identified by the use of words such as, but not limited to, “anticipates,” “believes,” “can,” “continues,” “could,” “estimates,” “expects,” “intends,” “may,” “will be,” “plans,” “projects,” “seeks,” “should,” “targets,” “will,” “would,” and similar expressions or variations intended to identify forward-looking statements. These statements are based on the beliefs and assumptions of our management based on information currently available to management. Such forward-looking statements are subject to risks, uncertainties and other important factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified below, and those discussed in the section titled “Risk Factors” included in our Annual Report on Form 10-K for the year ended December 31, 2017 filed on March 29, 2018, as subsequently amended on April 30, 2018 (the “2017 Annual Report”) and this Quarterly Report on Form 10-Q and any future reports we file with the Securities and Exchange Commission (“SEC”). The forward-looking statements set forth herein speak only as of the date of this report. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements, except as required by law.

All references in this Quarterly Report on Form 10-Q to “we,” “us” and “our” refer to XpresSpa Group, Inc., a Delaware corporation, and its condensed consolidated subsidiaries.

Overview

On January 5, 2018, we changed our name to XpresSpa Group, Inc. (“XpresSpa Group” or the “Company”) from FORM Holdings Corp. Our common stock, par value $0.01 per share, which had previously been listed under the trading symbol “FH” on the Nasdaq Capital Market, has been listed under the trading symbol “XSPA” since January 8, 2018. Rebranding to XpresSpa Group aligned our corporate strategy to build a pure-play health and wellness services company, which we commenced following our acquisition of XpresSpa Holdings, LLC (“XpresSpa”) on December 23, 2016.

XpresSpa is a well-recognized airport spa brand with 57 locations, consisting of 52 domestic and 5 international locations as of ~~March 31,~~September 30, 2018. It offers travelers premium spa services, including massage, nail and skin care, as well as spa and travel products. For the ~~three-month period~~three- and nine-month periods ended ~~March 31,~~September 30, 2018, approximately ~~86%~~80% and 83% of XpresSpa’s total revenue was generated by services, primarily massage and nailcare, and ~~14%~~20% and 17% was generated by retail products, primarily travel ~~accessories.~~accessories, respectively.

In October 2017, we completed the sale of FLI Charge, Inc. (“FLI Charge”) and in March 2018, we completed the sale of Group Mobile Int’l LLC (“Group Mobile”). The results of operations for FLI Charge and Group Mobile are presented in the condensed consolidated statements of operations and comprehensive loss as consolidated net loss from discontinued operations. The carrying amounts of assets and liabilities belonging to Group Mobile are presented in the condensed consolidated balance sheets as assets held for disposal and liabilities held for disposal, respectively, as of ~~March 31,~~September 30, 2018 and December 31, 2017.

We own certain patent portfolios, which we ~~now~~ look to monetize through sales and licensing agreements.

Q3 2018 Adjusted EBITDA Loss

Three months ended Three months ended
March 31, 2018 March 31, 2017
Products and services revenue $ 11,800,000 $ 10,984,000

Cost of sales
Labor (6,210,000 ) (5,309,000 )
Occupancy (2,060,000 ) (1,771,000 )
Products and other operating costs (1,443,000 ) (1,755,000 )
Total cost of sales (9,713,000 ) (8,835,000 )

Gross profit 2,087,000 2,149,000
Gross profit as a % of total revenue 17.7 % 19.6 %

Depreciation, amortization and impairment
Depreciation (1,047,000 ) (1,134,000 )
Amortization (606,000 ) (592,000 )
Goodwill impairment (19,630,000 ) —
Total depreciation, amortization and impairment (21,283,000 ) (1,726,000 )

Total general and administrative expense (4,596,000 ) (4,993,000 )

Other operating revenue and expense
Other operating revenue 800,000 100,000
Other operating expense (64,000 ) (99,000 )
Total other operating revenue, net 736,000 1,000

Operating loss from continuing operations (23,056,000 ) (4,569,000 )

Add:
Depreciation and amortization 1,653,000 1,726,000
Goodwill impairment 19,630,000 —
Merger and acquisition, integration, and one-time costs — 526,000
Stock-based compensation expense 312,000 547,000

Adjusted EBITDA loss $ (1,461,000 ) $ (1,770,000 )

	Three months ended September 30,						Nine months ended September 30,
	2018			2017			2018			2017
Products and services revenue	$	12,922,000		$	12,652,000		$	37,760,000		$	36,563,000

Cost of sales
Labor		(5,997,000	)		(7,086,000	)		(18,697,000	)		(18,178,000	)
Occupancy		(1,996,000	)		(1,950,000	)		(6,216,000	)		(5,704,000	)
Products and other operating costs		(1,966,000	)		(1,311,000	)		(5,092,000	)		(5,701,000	)
Total cost of sales		(9,959,000	)		(10,347,000	)		(30,005,000	)		(29,583,000	)

Gross profit		2,963,000			2,305,000			7,755,000			6,980,000
Gross profit as a % of total revenue		22.9	%		18.2	%		20.5	%		19.1	%

Depreciation, amortization and impairment
Depreciation		(1,195,000	)		(1,117,000	)		(3,474,000	)		(4,604,000	)
Amortization		(684,000	)		(605,000	)		(1,901,000	)		(1,775,000	)
Goodwill impairment		—			—			(19,630,000	)		—
Total depreciation, amortization and impairment		(1,879,000	)		(1,722,000	)		(25,005,000	)		(6,379,000	)

Total general and administrative expense		(3,943,000	)		(4,180,000	)		(12,443,000	)		(13,037,000	)

Other operating revenue and expense
Other operating revenue		—			200,000			800,000			300,000
Other operating expense		(26,000	)		(126,000	)		(116,000	)		(343,000	)
Total other operating revenue, net		(26,000	)		74,000			684,000			(43,000	)

Operating loss from continuing operations		(2,885,000	)		(3,523,000	)		(29,009,000	)		(12,479,000	)

Add:
Depreciation and amortization		1,879,000			1,722,000			5,375,000			6,379,000
Goodwill impairment		—			—			19,630,000			—
Merger and acquisition, integration, and one-time costs		452,000			529,000			1,057,000			1,365,000
Stock-based compensation expense		194,000			662,000			765,000			1,752,000

Adjusted EBITDA loss	$	(360,000	)	$	(610,000	)	$	(2,182,000	)	$	(2,983,000	)

We use GAAP and non-GAAP measurements to assess the trends in our business, including Adjusted EBITDA, a non-GAAP measure, which we define as earnings before interest, tax, depreciation and amortization expense, excluding merger and acquisition, integration and one-time costs and stock-based compensation.

Adjusted EBITDA is a supplemental measure of financial performance that is not required by, or presented in accordance with, GAAP. Reconciliations of operating loss for the ~~three-month~~three- and nine-month periods ended ~~March 31,~~September 30, 2018 and ~~March 31,~~September 30, 2017 to Adjusted EBITDA loss are presented in the tables above.

We consider Adjusted EBITDA to be an important indicator for the performance of our business, but not a measure of performance or liquidity calculated in accordance with ~~U.S.~~ GAAP. We have included this non-GAAP financial measure because management utilizes this information for assessing our performance and liquidity, and as an indicator of our ability to make capital expenditures and finance working capital requirements. We believe that Adjusted EBITDA is a measurement that is commonly used by analysts and some investors in evaluating the performance and liquidity of companies such as us. In particular, we believe that it is useful for analysts and investors to understand this indicator because it excludes transactions not related to our core cash operating activities. We believe that excluding these transactions allows investors to meaningfully analyze the performance of our core cash operations. Adjusted EBITDA should not be considered in isolation or as an alternative to cash flow from operating activities or as an alternative to operating income or as an indicator of operating performance or any other measure of performance derived in accordance with GAAP. In evaluating our performance as measured by Adjusted EBITDA, we recognize and consider the limitations of this measurement. Adjusted EBITDA does not reflect our obligations for the payment of income taxes, interest expense, or other obligations such as capital expenditures. Accordingly, Adjusted EBITDA is only one of the measurements ~~that management utilizes.~~utilized by management.

Results of Operations

Three-month period ended ~~March 31,~~September 30, 2018 compared to the three-month period ended ~~March 31,~~September 30, 2017

Revenue

Three months ended March 31,
2018 2017 Change
Revenue $ 12,600,000 $ 11,084,000 $ 1,516,000

	Three months ended September 30,
	2018		2017		Change
Revenue	$	12,922,000	$	12,852,000	$	70,000

During the three-month period ended ~~March 31,~~September 30, 2018, we recorded total revenue of ~~$12,600,000,~~$12,922,000, which represents an increase of ~~$1,516,000~~$70,000 (or ~~13.7%~~0.5%) compared to the three-month period ended ~~March 31,~~September 30, 2017. The increase in revenue was ~~a result~~primarily attributable to the number of XpresSpa locations open during each of the ~~opening of nine new~~three-month periods. There were 57 XpresSpa locations ~~and the closure~~open as of ~~five underperforming~~September 30, 2018 compared to 51 locations ~~during fiscal year 2017 and the opening~~open as of ~~three new XpresSpa locations and the closure of two underperforming locations during the first quarter of fiscal year 2018. Additionally, we have experienced an~~September 30, 2017. This increase was offset by a decrease in comparable store sales, which we define as current period sales from stores opened more than 12 months compared to those same stores’ sales in the prior year period. This decrease was largely due to airline reconfigurations and enplanement changes in three of our key terminals, which had a direct impact on traffic and ultimately revenues.

Cost of sales

	Three months ended September 30,
	2018		2017		Change
Cost of sales	$	9,985,000	$	10,473,000	$	(488,000	)

During the three-month period ended September 30, 2018, we recorded total cost of sales of $9,985,000, which represents a decrease of $488,000 (or 4.7%) compared to the three-month period ended September 30, 2017. This is consistent with the initiatives taken to streamline processes and reduce store-level costs which included reduced warehousing and shipping charges as we completed the transition of inventory sourcing to our strategic partner.

Included in cost of sales for the three-month period ended September 30, 2017 were intellectual property costs of $126,000, which included legal and consulting costs. There were no costs associated with intellectual property for the three-month period ended September 30, 2018.

Depreciation and amortization

	Three months ended September 30,
	2018		2017		Change
Depreciation and amortization	$	1,879,000	$	1,722,000	$	157,000

During the three-month period ended September 30, 2018, depreciation and amortization expense totaled $1,879,000, which represents an increase of $157,000 (or 9.1%), compared to the depreciation and amortization expense recorded during the three-month period ended September 30, 2017. The increase in depreciation and amortization expense was primarily due to a larger asset base during the three-month period ended September 30, 2018 due to a higher store count during the period.

General and administrative

	Three months ended September 30,
	2018		2017		Change
General and administrative	$	3,943,000	$	4,180,000	$	(237,000)

During the three-month period ended September 30, 2018, general and administrative expenses decreased by $237,000 (or 5.7%) compared to the three-month period ended September 30, 2017. This decrease was a result of streamlined processes at the corporate level to reduce administrative costs, as well as a reduction in stock-based compensation expense of $468,000 from $662,000 for the three-month period ended September 30, 2017 to $194,000 for the three-month period ended September 30, 2018. The overall decrease was partially offset by one-time professional fees of $348,000, and one-time project costs of $104,000 related to the buildout and implementation of a business analytics tool.

Non-operating expense, net

	Three months ended September 30,
	2018		2017		Change
Non-operating expense, net	$	246,000	$	265,000	$	(19,000	)

Net non-operating expenses include interest expense, gain or loss on the revaluation of derivative warrant liabilities and other non-operating income and expenses.

During the three-month period ended September 30, 2018, we recorded net non-operating expense of $246,000 compared to net non-operating expense of $265,000 recorded during the three-month period ended September 30, 2017.

For the three-month period ended September 30, 2018, we recorded interest expense of $183,000 related to the Debt with Rockmore, amortization of debt discount, debt issuance costs, and interest on the Convertible Notes of $440,000, and other non-operating expenses of $266,000, which includes $26,000 of loss on impairment related to the cost method investment in Marathon. These non-operating expenses were wholly offset by a gain of $643,000 on the revaluation of the derivative warrant liabilities that is reported as non-operating income.

For the three-month period ended September 30, 2017, we recorded interest expense of $183,000 related to the Debt and other non-operating expenses of $133,000. This non-operating expense was partially offset by a gain of $48,000 on the revaluation of the derivative warrant liabilities.

Nine-month period ended September 30, 2018 compared to the nine-month period ended September 30, 2017

Revenue

	Nine months ended September 30,
	2018		2017		Change
Revenue	$	38,560,000	$	36,863,000	$	1,697,000

During the nine-month period ended September 30, 2018, we recorded total revenue of $38,560,000, which represents an increase of $1,697,000 (or 4.6%) compared to the nine-month period ended September 30, 2017. The increase in revenue was mainly due to the opening of new XpresSpa locations during the fourth quarter of fiscal 2017 and the first three quarters of fiscal 2018, which resulted in a net increase of 6 new XpresSpa locations.

Additionally, during the ~~three-month~~nine-month period ended ~~March 31,~~September 30, 2018, we sold certain of our patents for consideration which included $250,000 and 250,000 shares of common stock in Marathon Patent Group, Inc. that were fair valued at $450,000. ~~Additionally,~~Also, in ~~both three-month periods~~each nine-month period ended ~~March 31,~~September 30, 2018 and ~~March 31,~~September 30, 2017, we entered into an executed confidential patent license agreement with a third-party for which we received a one-time lump sum payment of $100,000.

Cost of sales

Three months ended March 31,
2018 2017 Change
Cost of sales $ 9,777,000 $ 8,934,000 $ 843,000

	Nine months ended September 30,
	2018		2017		Change
Cost of sales	$	30,121,000	$	29,926,000	$	195,000

During the ~~three-month~~nine-month period ended ~~March 31,~~September 30, 2018, we recorded total cost of sales of ~~$9,777,000,~~$30,121,000, which represents an increase of ~~$843,000~~$195,000 (or ~~9.4%~~0.7%) compared to the ~~three-month~~nine-month period ended ~~March 31,~~September 30, 2017. This is consistent with the increase in revenues, as we have experienced an increase in cost of sales associated with labor and occupancy due to the opening of new stores during ~~fiscal year~~the fourth quarter of 2017 and the first ~~quarter~~three quarters of fiscal 2018. As of September 30, 3018 we had 57 locations compared to 51 locations as of September 30, 2017.

The overall increase in cost of sales due to the opening of new stores was partially offset by initiatives taken to streamline processes and reduce store-level costs which included reduced warehousing and shipping charges as we completed the transition of inventory sourcing to our strategic partner in the first half of 2018.

Cost of sales is expected to grow over time as our revenues increase. We expect that total cost of sales as a percentage of revenues will decline gradually over time as a result of the store-level performance improvements which we continue to prioritize.

Depreciation and amortization

Three months ended March 31,
2018 2017 Change
Depreciation and amortization $ 1,653,000 $ 1,726,000 $ (73,000 )

	Nine months ended September 30,
	2018		2017		Change
Depreciation and amortization	$	5,375,000	$	6,379,000	$	(1,004,000	)

During the ~~three-month~~nine-month period ended ~~March 31,~~September 30, 2018, depreciation and amortization expense totaled ~~$1,653,000,~~$5,375,000, which represents a decrease of ~~$73,000~~$1,004,000 (or ~~4.2%~~15.7%), compared to the depreciation and amortization expense recorded during the ~~three-month~~nine-month period ended ~~March 31,~~September 30, 2017. The decrease was primarily due to the disposal of certain property and equipment during ~~fiscal year~~the second quarter of 2017 ~~that reduced~~related to the ~~amount~~decision by management to perform a complete renovation of our flagship JFK location. Upon management’s decision to complete the ~~quarterly~~renovation, useful lives were revised to fully depreciate all remaining assets by the store close date. This resulted in an additional $1,100,000 of depreciation ~~expense.~~expense in the second quarter of 2017. This decrease was partially offset by depreciation expense related to the increase in the number of stores open during the nine-month period ended September 30, 2018 compared to the nine-month period ended September 30, 2017.

Goodwill impairment

Three months ended March 31,
2018 2017 Change
Goodwill impairment $ 19,630,000 $ — $ 19,630,000

	Nine months ended September 30,
	2018		2017		Change
Goodwill impairment	$	19,630,000	$	—	$	19,630,000

During the ~~three-month~~nine-month period ended ~~March 31,~~September 30, 2018, we recorded $19,630,000 of goodwill impairment expense. There was no goodwill impairment recorded during the ~~three-month~~nine-month period ended ~~March 31,~~September 30, 2017.

On January 5, 2018, we changed our name to XpresSpa Group as part of a rebranding effort to align our corporate strategy to build a pure-play health and wellness services company, which we commenced following our acquisition of XpresSpa on December 23, 2016. Following the subsequent sale of Group Mobile on March 22, 2018, which was the only remaining component of our technology operating segment, our management made the decision that our intellectual property operating segment would no longer be an area of focus and would no longer operate as a separate operating segment as it is not expected to generate any material revenues. This completed our transition into a pure-play health and wellness company with only one operating segment, consisting of our XpresSpa business.

During the first quarter of fiscal year 2018, our stock price declined from an opening price of $1.36 on January 2, 2018 to $0.72 on March 29, 2018. Subsequently, on April 19, 2018, we entered into a separation agreement with our Chief Executive Officer regarding his resignation as Chief Executive Officer and as our Director.

These events were identified by our management as triggering events requiring that goodwill be tested for impairment as of March 31, 2018. In addition to our rebranding efforts to a pure-play health and wellness services company, our stock price continued to decline even after the announcement of the new Chief Executive Officer. ~~Our stock price has averaged $0.67 following March 31, 2018.~~ As the stock price ~~has~~had not rebounded, we determined that the impairment ~~relates~~related to the three-month period ended March 31, 2018.

We performed testing on the estimated fair value of goodwill and, as a result, we recorded an impairment charge of $19,630,000 to reduce the carrying value of goodwill to its fair value, which was determined to be zero.

The impairment to goodwill was a result of the structural changes to the Company, including completion of the transition from a holding company to a ~~pure play~~pure-play health and wellness company and the change in Chief Executive Officer.

General and administrative

Three months ended March 31,
2018 2017 Change
General and administrative $ 4,596,000 $ 4,993,000 $ (397,000 )

	Nine months ended September 30,
	2018		2017		Change
General and administrative	$	12,443,000	$	13,037,000	$	(594,000	)

During the ~~three-month~~nine-month period ended ~~March 31,~~September 30, 2018, general and administrative expenses decreased by ~~$397,000~~$594,000 (or ~~8.0%~~4.6%) compared to the ~~three-month~~nine-month period ended ~~March 31,~~September 30, 2017. This decrease is a result of streamlined processes at the corporate level to reduce administrative costs, as well as a reduction in stock-based compensation expense of ~~$235,000~~$987,000 from ~~$547,000~~$1,752,000 for the ~~three-month~~nine-month period ended ~~March 31,~~September 30, 2017 to ~~$312,000~~$765,000 for the ~~three-month~~nine-month period ended ~~March 31,~~September 30, 2018. The overall decrease in general and administrative expenses was partially offset by severance costs of $350,000, one-time professional fees of $348,000, and one-time project costs of $359,000 related to the buildout and implementation of a business analytics tool, which we do not expect to recur in future periods.

Non-operating expense, net

Three months ended March 31,
2018 2017 Change
Non-operating expense, net $ (273,000 ) $ (75,000 ) $ (198,000 )

	Nine months ended September 30,
	2018		2017		Change
Non-operating expense, net	$	335,000	$	566,000	$	(231,000	)

Net non-operating expenses include interest expense, gain or loss on the revaluation of derivative warrant liabilities and other non-operating income and expenses.

During the ~~three-month~~nine-month period ended ~~March 31,~~September 30, 2018, we recorded net non-operating expense ~~in the amount~~ of ~~$273,000~~$335,000 compared to net non-operating expense ~~in the amount~~ of ~~$75,000~~$566,000 recorded during the ~~three-month~~nine-month period ended ~~March 31,~~September 30, 2017.

For the ~~three-month~~nine-month period ended ~~March 31,~~September 30, 2018, we recorded interest expense of ~~$183,000~~$548,000 related to ~~XpresSpa’s credit agreement and secured promissory note (the “Debt”)~~the Debt with Rockmore, ~~Investment Master Fund Ltd. (“Rockmore”)~~amortization of debt discount, debt issuance costs, and interest on the Convertible Notes of $663,000, and other non-operating expenses of ~~$123,000.~~$665,000, which includes $133,000 of loss on impairment related to the cost method investment in Marathon. These non-operating expenses were offset by a gain of ~~$33,000~~$1,541,000 on the revaluation of the derivative warrant liabilities that is reported as non-operating income.

For the ~~three-month~~nine-month period ended ~~March 31,~~September 30, 2017, we recorded interest expense of ~~$189,000~~$550,000 related to the ~~Debt.~~Debt and other non-operating expenses of $223,000. This non-operating expense was partially offset by a gain of ~~$26,000~~$207,000 on the revaluation of the derivative warrant ~~liabilities and additional non-operating income of $88,000.~~liabilities.

Liquidity and Capital Resources

Our primary liquidity and capital requirements are for new XpresSpa locations. As of ~~March 31,~~September 30, 2018, we had cash and cash equivalents of ~~$3,554,000.~~$2,525,000. We hold significant portions of our cash balance in overseas accounts, totaling $1,081,000, which is not insured by the Federal Deposit Insurance Corporation (“FDIC”). If we were to distribute the amounts held overseas, we would need to follow an approval process as it is defined in our operating and partnership agreements, which may delay the availability of our cash to us.

During the ~~three-month~~nine-month period ended ~~March 31,~~September 30, 2018, we incurred ~~$1,244,000~~$2,825,000 of capital expenditures, paid ~~$150,000~~$320,000 in debt issuance costs associated with the Convertible Notes, paid $738,000 of interest on the Debt and amortization of debt issuance costs related to the Convertible Notes, distributed ~~$220,000~~$1,265,000 to noncontrolling interests and spent ~~$2,184,000~~$4,180,000 on our operations. This was offset by the receipt of $250,000 from the sale of patents in January 2018 and the receipt of $800,000 from a note receivable that was paid in full in February 2018, as well as the receipt of $4,350,000 in gross proceeds from the issuance of Convertible Notes in May 2018. We expect to utilize our cash and cash equivalents, along with cash flows from operations, to provide capital to support the growth of our business, primarily through opening new XpresSpa locations, maintaining our existing XpresSpa locations and ~~maintaining~~supporting corporate functions. As of ~~March 31,~~September 30, 2018, we had approximately ~~$2,050,000~~$2,525,000 of cash and cash equivalents, $1,393,000 of inventory and prepaid expenses and ~~$717,000~~$109,000 of assets held for disposal, which amount to total current assets of ~~$6,321,000.~~$4,027,000. Our total current liabilities balance, which ~~include~~includes accounts ~~payables,~~payable, accrued expenses, and ~~accrued reserves were $8,560,000.~~the current portion of Convertible Notes, was $9,291,000 as of September 30, 2018. Included in total current liabilities is $1,610,000 of convertible notes classified as short-term for which principal repayments may be made in shares of Common Stock at our election. In addition, included in total current liabilities is approximately $1,661,000 which relates to obligations that will not settle in cash, and an additional $465,000 of liabilities that are not expected to settle in the next twelve months.

On May 15, 2018, we entered into a securities purchase agreement (the ~~“Agreement”~~“Securities Purchase Agreement”) with certain institutional investors (the “Investors”), pursuant to which we agreed to sell up to (i) an aggregate principal amount of $4,438,000 in 5% Secured Convertible Notes due on November 16, 2019, which ~~includes~~included $88,000 ~~to be~~ issued to Palladium Capital Advisors as Placement Agent (the “Convertible Notes”), convertible into shares of our common stock, par value $0.01 per share (the “Common Stock”) at a conversion price of $0.62 per share, (ii) Class A Warrants (the “Class A Warrants”) to purchase 7,157,259 shares of Common Stock at an exercise price of $0.62 per share and (iii) Class B Warrants (the “Class B Warrants,” and together with the Class A Warrants, the “Warrants”) to purchase 3,578,630 shares of Common Stock at an exercise price of $0.62 per share. The Convertible Notes bear interest at a rate of 5% per annum. The Convertible Notes are senior secured obligations of ours and are secured by certain of our personal property. Unless earlier converted or redeemed, the Convertible Notes will mature on November 16, 2019. The transaction closed on May 17, 2018, at which time we received $4,350,000 in ~~November 2019.~~gross proceeds from the Investors.

The principal amount of the outstanding Convertible Notes is to be repaid monthly in the amount of approximately $296,000, beginning inon September 17, 2018, and we may make such payments and related interest payments in cash or, subject to certain conditions, in registered shares of our common stock (or a combination thereof), at our election. If we choose to repay the Convertible Notes in shares of our common stock, the shares will be issued at a 10% discount to the volume weighted average price of our common stock for the five (5) trading days commencing eight (8) days prior to the relevant repayment date and ending on the fourth (4^th) trading day prior to such repayment date, subject to a minimum floor price of not less than 20% of the conversion price of the Convertible Notes on the issue date. We may also repay the Convertible Notes in advance of the maturity schedule subject to an early repayment ~~penalties~~penalty of 15%.

On August 14, 2018, we entered into an Amendment Agreement (“Amendment Agreement”) whereby the initial monthly principal repayment and accrued interest due on the Convertible Notes of $351 was settled in 2,067 shares of Common Stock on August 15, 2018. All other material terms of the Securities Purchase Agreement remained unchanged. During the three-month period ended September 30, 2018, several of the Investors converted their monthly principal payments and accrued interest due on the Convertible Notes into shares of Common Stock pursuant to the Amendment Agreement, resulting in the issuance of an additional 2,737 shares of Common Stock.

Our management believes that our current cash balance, ~~the issuance of the Convertible Notes and Warrants, and~~ cash to be provided by future operating activities, and cash proceeds from the anticipated liquidation of certain investments, will be sufficient to fund our planned operations and ~~scheduled Convertible Notes principal repayments~~pay our liabilities as they become due for at least the next twelve ~~months following the date~~months. At our election, principal repayments of the ~~filing~~Convertible Notes may be made in cash or, subject to certain conditions, in registered shares of ~~these financial statements.~~our common stock. In addition, we have access to additional sources of financing and may attempt to renegotiate terms of various contracts.

On November 12, 2018, we entered into a Product Sale and Marketing Agreement (the “Collaboration Agreement”) with Calm.com, Inc. (“Calm”) primarily related to the display, marketing, promotion, offer for sale and sale of Calm’s products in each of our branded stores throughout the United States. The Collaboration Agreement resulted in an initial investment by Calm of $2,000,000 in Series E Preferred Stock, convertible into shares of Common Stock at $0.62 per share, which was received upon the closing of the transaction.

Off-Balance Sheet Arrangements

We have no obligations, assets or liabilities which would be considered off-balance sheet arrangements. We do not participate in transactions that create relationships with unconsolidated entities or financial partnerships, often referred to as variable interest entities, which would have been established for the purpose of facilitating off-balance sheet arrangements.

Critical Accounting Estimates

These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in our Annual Report on Form 10-K filed with the SEC on March 29, 2018, as subsequently amended on April 30, 2018, which includes a description of our critical accounting policies that involve subjective and complex judgments that could potentially affect reported results. While there have been no material changes to our critical accounting policies as to the methodologies or assumptions we apply under them, we continue to monitor such methodologies and assumptions.

Item 3.

Quantitative and Qualitative Disclosures About Market Risk.

Not required as we are a smaller reporting company.

Item 4.

Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) promulgated under the Exchange ~~Act~~Act) that are designed to ensure that information required to be disclosed in Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and ~~Chief~~Principal Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

As of ~~March 31,~~September 30, 2018, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and ~~Chief~~Principal Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based on the foregoing, our Chief Executive Officer and ~~Chief~~Principal Financial Officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report.

Changes in Internal Control over Financial Reporting

There has been no change in our internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the quarter ended ~~March 31,~~September 30, 2018 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Part II– OTHER INFORMATION

Item 1.

Legal Proceedings.

For information regarding legal proceedings, see Note 1213 “Commitments and Contingencies” in our notes to the condensed consolidated financial statements included in “Item 1. Financial Statements.”

Item 1A.

Risk Factors.

~~There~~Other than as set forth below, there have been no material changes to the risk factors discussed in Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2017.

Our business and financial condition could be constrained by XpresSpa’s outstanding debt, and/or failure to make payments on XpresSpa’s outstanding debt.

XpresSpa is obligated under the Senior Secured Note payable to Rockmore Investment Master Fund Ltd. (“Rockmore”), a related party, which has an outstanding balance of $6,500,000, with a maturity date of December 31, 2019. The Senior Secured Note accrues interest of 11.24% per annum. XpresSpa is obligated to make periodic payments on such debt obligations to Rockmore. While we do not anticipate failing to make any such debt payments, the failure to do so may result in the default of loan obligations, leading to financial and operational hardship. In addition, XpresSpa has granted Rockmore a security interest in all of its tangible and intangible personal property to secure its obligations under the Senior Secured Note. The Senior Secured Note is an outstanding obligation of XpresSpa but is guaranteed by us.

Our business and financial condition could be constrained by our outstanding debt and/or failure to make payments on such outstanding debt.

We are obligated under the Convertible Notes issued to the Investors pursuant to the Securities Purchase Agreement, which collectively had an outstanding unamortized book balance of approximately $2,008,000 as of September 30, 2018, and a total fair value upon issuance of $4,350,000, with maturity dates of November 16, 2019 and which accrue interest at an annual rate of 5%. We are obligated to make periodic payments on such debt obligations to each debtholder; and we can elect to make such payments either in cash or in stock. In addition, we have granted a security interest to the Investors in all of our tangible and intangible personal property to secure our obligations under the Convertible Notes issued to the Investors pursuant to the Securities Purchase Agreement.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3.

Defaults Upon Senior Securities.

None.

Item 4.

Mine Safety Disclosures.

Not applicable.

Item 5.

Other Information.

~~Private Placement Offering~~Collaboration Agreement

On ~~May 15,~~November 12, 2018, the Company entered into a ~~securities~~Product Sale and Marketing Agreement (the “Collaboration Agreement”) with Calm.com, Inc. (“Calm”) primarily related to the display, marketing, promotion, offer for sale and sale of Calm’s products in each of the Company’s branded stores throughout the United States.

The Collaboration Agreement shall remain in effect until July 31, 2019, unless terminated earlier in accordance with the Collaboration Agreement, and automatically renew for successive terms of six (6) months unless either party provides written notice of termination no later than thirty (30) days prior to any such automatic renewal of the Collaboration Agreement.

Stock Purchase Agreement

In connection with the entry into the Collaboration Agreement, the Company entered into a stock purchase agreement (the “Purchase Agreement”) with ~~certain accredited investors (the “Investors”),~~Calm, pursuant to which the Company ~~agreed~~issued to ~~sell (the “Offering”) up to (i)~~Calm an aggregate ~~principal amount~~ of ~~$4,438,000 in 5% Secured Convertible Notes due 2019, which includes $88,000 issued to Palladium Capital Advisors as Placement Agent (the “Convertible Notes”), convertible into~~645,161 shares of ~~common stock of~~ the ~~Company,~~Company’s newly designated Series E Convertible Preferred Stock, par value $0.01 per share ~~(“Common~~(the “Series E Preferred Stock”), which is initially convertible into 3,225,806 shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”) at a conversion price of $0.62 per share, ~~(ii) Class A Warrants~~subject to certain adjustments. The purchase ~~7,157,259 shares of Common Stock at an exercise~~ price ~~of $0.62~~ per share ~~(the “Class A Warrants”) and (iii) Class B Warrants to purchase 3,578,630 shares~~ of ~~Common~~the Series E Preferred Stock ~~at an exercise price of $0.62~~was $3.10 per share ~~(the “Class B Warrants,” and together with the Class A Warrants, the “Warrants”). The Company expects to receive $4,350,000 in~~for gross proceeds ~~from~~to the ~~Offering. The~~ Company ~~expects~~of $2,000,000. In addition, on or before December 31, 2018 and subject to ~~close~~ the ~~transaction as soon as possible following the filing of these financial statements.~~

~~Securities Purchase Agreement~~

~~The Purchase Agreement contains representations and warranties~~satisfaction of the ~~Company and the Investors which are typical for transactions of this type. In addition,~~conditions under the Purchase Agreement, ~~contains customary covenants on~~the Company shall sell, and Calm shall purchase, 322,581 additional shares of Series E Preferred Stock (the “Additional Series E Shares”), which will initially be convertible into 1,612,905 shares of the Company’s part that are typical for transactions of this type, as well as the following additional covenants: (i) until no Investor holds less than 10% of the Convertible Notes originally issued to such Investor, the Company agreed not to enter into any variable rate transactions; (ii) the Company agreed to offer to the Investors, until one year after the Closing, the opportunity to participate in any subsequent securities offerings by the Company; (iv) the Company agreed to use its commercially reasonable efforts to hold a stockholder meeting within 120 days of the Closing Date at which the Company will solicit the stockholders’ affirmative vote for approval of its issuance of certain shares issuable upon conversion of the Convertible Notes and the exercise of the Warrants described in the transaction documents in accordance with the applicable law and rules and regulations of the Nasdaq Stock Market (“Nasdaq”).

The Purchase Agreement obligates the Company to indemnify the Investors and various related parties for certain losses including those resulting from (i) any misrepresentation or breach of any representation or warranty made by the Company, (ii) any breach of any obligation of the Company, and (iii) certain claims by third parties.

~~Convertible Notes and Warrants~~

The Convertible Notes are senior secured obligations of the Company and are secured by certain personal property of the Company, pursuant to a Security Agreement (as defined below). Unless earlier converted or redeemed, the Convertible Notes will mature in November 2019. The Convertible Notes bear interest at a rate of 5% per annum, subject to increase in the event of default to the lesser of 18% per annum or the maximum rate permitted under applicable law. The Convertible Notes, including interest accrued thereon, are convertible at any time until a Convertible Note is no longer outstanding, in whole or in part, at the option of the holders into shares of Common Stock at a conversion price of $0.62 per ~~share. The Convertible Notes have a beneficial ownership limitation such that none~~share, subject to certain adjustments, for gross proceeds to the Company of $1,000,000, which sale of Additional Series E Shares shall be on the same terms and conditions as those contained in the Purchase Agreement.

Series E Preferred Stock

On November 12, 2018, the Company filed with the Secretary of State of the ~~Investors~~State of Delaware a Certificate of Designation of Preferences, Rights and Limitations of Series E Convertible Preferred Stock (the “Certificate of Designations”). Pursuant to the Certificate of Designations, the holders of the Series E Preferred Stock are entitled, among other things, to an aggregate initial liquidation preference of $2,000,000 ($3,000,000 if the Second Closing occurs) and the right to participate in any dividends and distributions paid to common stockholders on an as-converted basis. The Series E Preferred Stock will vote on an as-converted basis. The Series E Preferred Stock is convertible at any time and from time to time without the payment of additional consideration and has a stated value of $3.10 per share of Series E Preferred Stock. In the event of any liquidation or dissolution of the Company, the Series E Preferred Stock ranks senior to any other class of preferred stock and to the Common Stock in the distribution of assets, to the extent legally available for distribution.

Pursuant to the terms of the Certificate of Designations, on the seven (7) year anniversary of the initial issuance date of the shares of Series E Preferred Stock, the Company may repay each share of the Series E Preferred Stock, at its option, in cash, by delivery of Common Stock or through any combination thereof. Additionally, under certain conditions, the Company may have the right, but not the obligation to convert the outstanding shares of Series E Preferred Stock into Common Stock. If the Company elects to make a payment, or any portion thereof, in shares of ~~their Convertible Notes if~~Common Stock, the ~~Investor (together with its affiliates or any other persons acting together as a group with~~number of shares deliverable (the “Base Shares”) will be based on the ~~Investor) would beneficially own in excess~~volume weighted average price (the “VWAP”) per share of ~~9.99%~~Common Stock for the thirty (30) trading days prior to the date of ~~the~~calculation (the “Base Price”) plus an additional number of shares of Common Stock ~~outstanding immediately after giving effect~~(the “Premium Shares”), calculated as follows: (i) if the Base Price is greater than $9.00, no Premium Shares shall be issued, (ii) if the Base Price is greater than $7.00 and equal to or less than $9.00, an additional number of shares equal to 5% of the ~~issuance~~Base Shares shall be issued, (iii) if the Base Price is greater than $6.00 and equal to or less than $7.00, an additional number of shares equal to 10% of the Base Shares shall be issued, (iv) if the Base Price is greater than $5.00 and equal to or less than $6.00, an additional number of shares equal to 20% of the Base Shares shall be issued and (v) if the Base Price is less than or equal to $5.00, an additional number of shares equal to 25% of the Base Shares shall be issued. Accordingly, if the volume weighted average price per share of Common Stock ~~issuable upon conversion~~is below $9.00 per share at the time of ~~such Convertible Notes. In addition, the Convertible Notes provide for a conversion cap such that~~repayment and the Company ~~may not issue any~~exercises the option to make such repayment in shares of Common Stock, ~~upon conversion of Convertible Notes which would exceed the aggregate~~a large number of shares of Common Stock may be issued to the holders of Series E Preferred Stock upon maturity, which may have a negative effect on the trading price of Common Stock. At the seven (7) year maturity date of the Series E Preferred Stock, the Company, ~~could~~at its election, may decide to issue ~~upon conversion of the Convertible Notes without breaching its obligations, if any, under Nasdaq rules and regulations.~~

Interest on the Convertible Notes is payable in arrears beginning in September 2018, on the four-month anniversary of the issuance of the Convertible Notes, and is payable on each monthly anniversary thereafter, including at maturity when all amounts outstanding under the Convertible Notes become due and payable (each a “Payment Date”). The Company may elect to pay interest in cash, shares of Common Stock based on the formula set forth above or ~~a combination thereof. On each Payment Date, the Company must also make payments~~ to ~~the Investors~~re-pay in ~~an amount equal to 6.67%~~cash all or any portion of the ~~initial principal amount~~Series E Preferred Stock. However, in no event, shall the VWAP per share of Common Stock be determined to be less than $0.62.

In 2025, upon the maturity date of the ~~outstanding Convertible Notes (the “Monthly Principal Amount”). The Company may elect~~Series E Preferred Stock, when determining whether to ~~pay~~repay the ~~Monthly Principal Amount~~Series E Preferred Stock in cash or shares of Common Stock, ~~(or~~the Company expects to consider a ~~combination~~number of factors, including its cash ~~and shares of Common Stock) (a “Principal Share Payment”), subject to certain conditions. A Principal Share Payment will be determined by dividing~~position, the Monthly Principal Amount by ninety percent (90%) of the daily volume weighted average price, or VWAP, as defined and determined under the Convertible Notes, for the five (5) trading days beginning on the eighth (8^th~~) trading day prior to the relevant Payment Date and ending on the fourth (4~~^th~~) trading day preceding such Payment Date. Notwithstanding the foregoing, the Principal Share Repayment shall not be less than 20% of the conversion~~ price of the ~~Convertible Notes on~~Common Stock and the ~~date of issuance unless~~Company’s capital structure at such time. Because the Company does not have to make a determination as to which option to elect until 2025, it is ~~not then subject~~impossible to ~~Nasdaq listing rule 5635(d)~~predict whether it is more or ~~if approved by Nasdaq.~~less likely to repay in cash, stock or a portion of each.

IfIn addition, the ~~Company receives gross~~Series E Preferred Stock contains certain protective provisions that limit the Company’s ability to make certain cash ~~proceeds~~distributions or payment of ~~$10,000,000 or more~~any indebtedness without the written consent of the holders of a majority of the outstanding shares of Series E Preferred Stock.

The shares of Series E Preferred Stock sold and issued in connection with ~~a closing of an offering of its securities,~~ the Convertible Notes require the Company to make an offer to the Investors to repay an Investor’s pro rata portion of the net proceeds, if such a closing occurs, of up to 100% of the Investor’s principal amount of Convertible Notes and accrued but unpaid interest designated by the Investor. Beginning four months after issuance, the Company has the option to prepay the outstanding principal amount of Convertible Notes, in whole or in part, by paying to the Investor 115% of the principal amount to be redeemed, together with accrued but unpaid interest, if any, and any other sums due, accrued or payable to the Investor under the Convertible Notes.

The Convertible Notes also contain certain negative covenants, including prohibitions on the incurrence of indebtedness, liens, amendments to the Company’s organizational documents, dividends, redemption, related party transactions and entry into any equity line of credit agreement or variable rate transactions. The Convertible Notes also contain standard and customary events of default including, butPurchase Agreement are not limited to, failure to make payments when due, failure to observe or perform covenants or agreements contained in the Convertible Notes, existence of a default or event of default under any of the Transaction Documents (as defined in the Convertible Notes), the bankruptcy or insolvency of the Company or any of its subsidiaries and unsatisfied judgments against the Company.

The Class A Warrants and Class B Warrants entitle the holders to purchase 7,157,259 and 3,578,630 shares of Common Stock, respectively. The Class A Warrants are exercisable beginning six months from the date of issuance and have a term of five years. The Class B Warrants are exercisable beginning six months from the date of issuance and have a term of six months. The Class A Warrants and Class B Warrants each have an exercise price of $0.62 per share.

The terms of the each of the Convertible Notes and the Warrants provide for anti-dilution protection for issuances of Common Stock at a price per share less than the price equal to the conversion price or exercise price, as applicable, subject to approval by the Company’s stockholders. In the event of a “fundamental transaction” (as defined in the Warrants), the Investors will have the right to receive the value of the Warrants as determined in accordance with the Black Scholes option pricing model.

~~The Convertible Notes, Warrants and the shares of common stock issuable upon conversion and exercise of the Convertible Notes and Warrants (the “Underlying Shares”) have not been~~ registered under the Securities Act ~~of 1933, as amended (the “Securities Act”)~~or any state securities laws and were issued and sold in reliance upon the exemption from registration contained in Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D promulgated thereunder. Each Investor acquired the securities for investment and acknowledged that it is an accredited investor as defined by Rule 501 under the Securities Act. The Convertible Notes, Warrants and Underlying Shares may not be offered or sold in the ~~absence of~~United States absent registration with the SEC or an ~~effective registration statement or~~applicable exemption from the registration ~~requirements under the Securities Act.~~requirements.

~~Registration Rights Agreement~~Seniority to Series D Convertible Preferred Stock

In connection with the entry into the Purchase Agreement, a majority of the ~~Company and~~holders of the ~~Investors entered into a Registration Rights Agreement~~Company’s Series D Convertible Preferred Stock (the ~~“Registration Rights Agreement”~~“Series D Preferred Stock”)~~, pursuant to which the Company has~~ agreed to ~~register~~waive the ~~Underlying Shares on a registration statement on Form S-3 (the “Registration Statement”)~~provisions of the Certificate of Designation of Preferences, Rights and Limitations of Series D Convertible Preferred Stock prohibiting any class of stock existing senior to ~~be filed~~the Series D Preferred Stock with respect to right of participation in any dividends and distributions. Upon the ~~United States Securities and Exchange Commission (the “SEC”) within forty-five (45) days after the date~~issuance of the issuance of the ~~Convertible Notes and Warrants and to cause~~Series E Preferred Stock, the Registration Statement to be declared effective under the Securities Act of 1933, as amended (the “Securities Act”). If certain of the Company’s obligations under the Registration Rights Agreement are not met, the Company is required to pay partial liquidated damagesSeries D Preferred Stock will rank junior to the ~~Investors.~~Series E Preferred Stock with respect to the Series E Preferred Stock’s initial liquidation preference and in right of participation in any dividends and distributions.

~~Security Agreement~~Certificate of Designation

On November 13, 2018, the Company filed the Certificate of Designations with the Secretary of State of the State of Delaware, establishing and designating the rights, powers and preferences of the Series E Preferred Stock. The Company ~~also entered into a Security Agreement (the “Security Agreement”) with Alpha Capital Anstalt, as collateral agent (the “Collateral Agent”), the Investors and such holders~~designated up to 1,473,300 shares of the Convertible Notes as may be issued in the future (together with the Investors, the “Secured Parties”). Pursuant to the Security Agreement, the Secured Parties were granted a security interest in certain of the Company’s personal property to secure the payment and performance of all of the Company’s obligations under the Convertible Notes, Warrants, Purchase Agreement, Registration Rights Agreement and Security Agreement (together, the “Transaction Documents”). In addition, in connection the Security Agreement, certain of the Company’s subsidiaries executed a subsidiary guaranty (each a “Subsidiary Guarantor,” and together the “Subsidiary Guarantors”), pursuant to which the Subsidiary Guarantors agreed to guarantee and act as surety for the payment of the Convertible Notes and other of the Company’s obligations under the Transaction Documents. The Convertible Notes will be effectively subordinated to an existing secured promissory note, as amended (the “Senior Note”), and all of the Company’s obligations under the Senior Note (together the “Senior Debt”) held by Rockmore Investment Master Fund Ltd. (“Rockmore” or the “Senior Lender”) until the Senior Debt is paid in full.Series E Preferred Stock.

The foregoing ~~descriptions~~summaries of the Purchase Agreement ~~Registration Rights Agreement, Security Agreement, Convertible Notes~~ and ~~Warrants are incomplete,~~Certificate of Designations do not purport to be complete and are ~~subject to, and~~ qualified in their entirety by reference to the ~~full text~~Purchase Agreement and Certificate of ~~thereof, copies of each of~~Designations, which are attached hereto as ~~exhibits 10.8, 10.9, 10.10, 4.1, 4.2~~Exhibits 10.1 and ~~4.3,~~3.1, respectively, ~~each of which is~~to this Quarterly Report on Form 10-Q and are incorporated ~~herein in its entirely~~ by ~~reference.~~reference herein.

~~Exemption under the Company’s Section 382 Rights Agreement~~

The Company’s board of directors has previously adopted a Section 382 Rights Agreement, dated as of March 18, 2016, between the Company and American Stock Transfer & Trust Company, LLC, as rights agent (the “Rights Agreement”) to protect stockholder value by deterring acquisitions of the Company’s common stock that would potentially limit the Company’s ability to use its net operating loss carryforwards (“NOLs”) and other tax benefits, which may be used to reduce potential future income tax obligations. In general, the rights issued under the Rights Agreement impose a significant penalty to any person, together with its Affiliates (as defined in the Rights Agreement), that acquires 4.99% or more of the Company’s common stock, unless such person is an “Exempt Person” or is otherwise excluded from the Rights Agreement.

In connection with the Offering, the Company has granted an exemption to Alpha Capital Anstalt (“Alpha”) under the Rights Agreement, following the determination by the board of directors of the Company that Alpha is an “Exempt Person” pursuant to Section 29 of the Rights Agreement.

~~Rockmore Debt~~

On May 14, 2018, the Company and Rockmore agreed to extend the maturity date of the credit agreement and secured promissory note (the “Debt”) from May 1, 2019 to December 31, 2019. No other material terms of the Debt were modified.

Item 6.

~~Exhibits~~Exhibits..

Exhibit No.		Description
4.1*		~~Form of Convertible Note.~~

4.23.1		~~Form~~Certificate of ~~Class A Warrant.~~

4.3*		~~Form~~Designation of ~~Class B Warrant.~~Preferences, Rights and Limitations of Series E Convertible Preferred Stock.

10.1*		~~Credit agreement dated as of April 22, 2015, by and between XpresSpa Holdings, LLC and Rockmore Investment Master Fund Ltd.~~

10.2*		~~First Amendment to Credit Agreement and Conditional Waiver dated as of August 8, 2016, by and between XpresSpa Holdings, LLC and Rockmore Investment Master Fund Ltd.~~

10.3*		~~Second Amendment to Credit Agreement dated as of May 10, 2017, by and between XpresSpa Holdings, LLC and B3D, LLC.~~

10.4*		~~Third Amendment to Credit Agreement dated as of May 14, 2018, by and between XpresSpa Holdings, LLC and B3D, LLC.~~

10.5*		~~Security Agreement dated as of April 22, 2015, by and between XpresSpa Holdings, LLC and Rockmore Investment Master Fund Ltd.~~

10.6*		~~Supplement No. 1 to Security Agreement dated as of May 18, 2015, by and between XpresSpa Holdings, LLC and Rockmore Investment Master Fund Ltd.~~

10.7*		~~Supplement No. 2 to Security Agreement dated as of December 20, 2017, by and between XpresSpa Holdings, LLC and Rockmore Investment Master Fund Ltd.~~

10.8*		Form of ~~Securities~~Stock Purchase Agreement, dated ~~May 15,~~November 12, 2018, by and among the Company and ~~the Investors.~~

10.9*		~~Form of Registration Rights Agreement, dated May 15, 2018, by and among the Company and the Investors.~~

10.10*		~~Form of Security Agreement, dated May 15, 2018, by and among the Company, the Subsidiaries, the Collateral Agent and the Investors.~~Calm.com, Inc.

31.1*		Certification of Principal Executive Officer pursuant to Exchange Act, Rules 13a - 14(a) and 15d - 14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2*		Certification of Principal Financial Officer pursuant to Exchange Act Rules 13a - 14(a) and 15d - 14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32**		Certifications of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS*		XBRL Instance Document

101.SCH*		XBRL Taxonomy Extension Schema Document

101.CAL*		XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF*		XBRL Taxonomy Extension Definition Linkbase Document

101.LAB*		XBRL Taxonomy Extension Label Linkbase Document

101.PRE*		XBRL Taxonomy Extension Presentation Linkbase Document

*		Filed herewith.
**		Furnished herein.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized on the ~~15th~~14th day of ~~May~~November, 2018.

XpresSpa Group, Inc.

~~XpresSpa Group, Inc.~~

By:	/s/ ~~ANASTASIA NYRKOVSKAYA~~EDWARD JANKOWSKI
	~~Anastasia Nyrkovskaya~~Edward Jankowski
	Chief ~~Financial~~Executive Officer
	(Principal Executive Officer)

By:	/s/ JANINE CANALE
	Janine Canale
	Controller
	(Principal Financial and Accounting Officer)

Delaware		20-4988129
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

780 Third Avenue, 12th Floor, New York, NY		10017
(Address of principal executive offices)		(Zip Code)

Title of each class		Name of each exchange on which registered
Common Stock, par value $0.01 per share		The Nasdaq Stock Market LLC

Large accelerated filer	¨	Accelerated filer	¨
Non-accelerated filer	¨x	Smaller reporting company	x
~~(Do not check if a smaller reporting company)~~		Emerging growth company	¨

		Page
PART I. FINANCIAL INFORMATION		3

Item 1.	Condensed Consolidated Financial Statements	3
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	2027
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	2434
Item 4.	Controls and Procedures	2434

PART II. OTHER INFORMATION		2535

Item 1.	Legal Proceedings	2535
Item 1A.	Risk Factors	2535
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	2535
Item 3.	Defaults Upon Senior Securities	2535
Item 4.	Mine Safety Disclosures	2535
Item 5.	Other Information	2536
Item 6.	Exhibits	2838

	March 31, 2018 (Unaudited)			December 31, 2017
Current assets
Cash and cash equivalents	$	3,554		$	6,368
Inventory		1,050			1,159
Other current assets		1,000			2,120
Assets held for disposal		717			6,446
Total current assets		6,321			16,093

Restricted cash		487			487
Property and equipment, net		15,928			15,797
Intangible assets, net		11,007			11,547
Goodwill		—			19,630
Other assets		3,765			1,686
Total assets	$	37,508		$	65,240

Current liabilities
Accounts payable, accrued expenses and other current liabilities	$	8,560		$	8,736
Liabilities held for disposal		—			3,761
Total current liabilities		8,560			12,497

Debt		6,500			6,500
Other liabilities		433			404
Total liabilities		15,493			19,401
Commitments and contingencies (see Note 12)

Stockholders’ equity
Series A Convertible Preferred stock, $0.01 par value per share; 500,000 shares authorized; 6,968 issued and none outstanding		—			—
Series B Convertible Preferred stock, $0.01 par value per share; 5,000,000 shares authorized; 1,666,667 issued and none outstanding		—			—
Series C Junior Preferred stock, $0.01 par value per share; 300,000 shares authorized; none issued and outstanding		—			—
Series D Convertible Preferred Stock, $0.01 par value per share; 500,000 shares authorized; 475,208 shares issued and 420,541 shares outstanding with a liquidation value of $20,186 as of March 31, 2018 and December 31, 2017		4			4
Common stock, $0.01 par value per share; 150,000,000 shares authorized; 26,634,475 and 26,545,690 issued and outstanding as of March 31, 2018 and December 31, 2017, respectively		266			265
Additional paid-in capital		290,707			290,396
Accumulated deficit		(273,641	)		(249,708	)
Accumulated other comprehensive loss		(140	)		(74	)
Total stockholders’ equity attributable to the Company		17,196			40,883
Noncontrolling interests		4,819			4,956
Total stockholders’ equity		22,015			45,839
Total liabilities and stockholders’ equity	$	37,508		$	65,240

	Three months ended March 31,
	2018			2017
Revenue	$	2,834		$	3,525
Cost of sales		(2,305	)		(2,960	)
Depreciation and amortization		(131	)		(173	)
General and administrative		(680	)		(1,868	)
Loss on disposal		(301	)		—
Non-operating expense		(22	)		(2	)
Loss from discontinued operations before income taxes		(605	)		(1,478	)
Income tax expense		—			—
Consolidated net loss from discontinued operations	$	(605	)	$	(1,478	)

	Three months ended			Three months ended
	March 31, 2018			March 31, 2017
Products and services revenue	$	11,800,000		$	10,984,000

Cost of sales
Labor		(6,210,000	)		(5,309,000	)
Occupancy		(2,060,000	)		(1,771,000	)
Products and other operating costs		(1,443,000	)		(1,755,000	)
Total cost of sales		(9,713,000	)		(8,835,000	)

Gross profit		2,087,000			2,149,000
Gross profit as a % of total revenue		17.7	%		19.6	%

Depreciation, amortization and impairment
Depreciation		(1,047,000	)		(1,134,000	)
Amortization		(606,000	)		(592,000	)
Goodwill impairment		(19,630,000	)		—
Total depreciation, amortization and impairment		(21,283,000	)		(1,726,000	)

Total general and administrative expense		(4,596,000	)		(4,993,000	)

Other operating revenue and expense
Other operating revenue		800,000			100,000
Other operating expense		(64,000	)		(99,000	)
Total other operating revenue, net		736,000			1,000

Operating loss from continuing operations		(23,056,000	)		(4,569,000	)

Add:
Depreciation and amortization		1,653,000			1,726,000
Goodwill impairment		19,630,000			—
Merger and acquisition, integration, and one-time costs		—			526,000
Stock-based compensation expense		312,000			547,000

Adjusted EBITDA loss	$	(1,461,000	)	$	(1,770,000	)